{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:03:20Z","timestamp":1792109000403,"version":"4.4.0"},"reference-count":513,"publisher":"Sociedade Brasileira de Cardiologia","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,15]]},"DOI":"10.36660\/abc.20210180","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T14:26:36Z","timestamp":1626704796000},"page":"181-264","source":"Crossref","is-referenced-by-count":63,"title":["Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Inst\u00e1vel e Infarto Agudo do Mioc\u00e1rdio sem Supradesn\u00edvel do Segmento ST \u2013 2021"],"prefix":"10.36660","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1381-6442","authenticated-orcid":false,"given":"Jos\u00e9 Carlos","family":"Nicolau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8379-6192","authenticated-orcid":false,"suffix":"Filho","given":"Gilson Soares","family":"Feitosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4598-5512","authenticated-orcid":false,"given":"Jo\u00e3o Luiz","family":"Petriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4639-1003","authenticated-orcid":false,"given":"Remo Holanda de Mendon\u00e7a","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1187-8690","authenticated-orcid":false,"given":"Dalton Bertolim","family":"Pr\u00e9coma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walmor","family":"Lemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-4961","authenticated-orcid":false,"given":"Renato Delascio","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6751-0721","authenticated-orcid":false,"given":"Ari","family":"Timerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8651-8833","authenticated-orcid":false,"suffix":"Neto","given":"Jos\u00e9 A.","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4600-204X","authenticated-orcid":false,"suffix":"Neto","given":"Luiz","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Ferraz de Oliveira","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4800-0849","authenticated-orcid":false,"given":"Eduardo Cavalcanti Lapa","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-817X","authenticated-orcid":false,"given":"Leopoldo Soares","family":"Piegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre de Matos","family":"Soeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Jorge de Andrade","family":"Negri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3201-9561","authenticated-orcid":false,"given":"Andre","family":"Franci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3068-0540","authenticated-orcid":false,"suffix":"Filho","given":"Brivaldo","family":"Markman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Mendon\u00e7a","family":"Baccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo Lucena","family":"Montenegro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4505-3344","authenticated-orcid":false,"given":"Carlos Eduardo","family":"Rochitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Jos\u00e9 Dornas Gon\u00e7alves","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udio Marcelo Bittencourt das","family":"Virgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edson","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1592-4727","authenticated-orcid":false,"given":"Euler Roberto Fernandes","family":"Manenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Gallego","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"J\u00fanior","given":"Francisco das Chagas","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Filho","given":"Harry","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique Patrus Mundim","family":"Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibraim Masciarelli Francisco","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Luiz de Alencar Araripe","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joberto Pinheiro","family":"Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2684-0142","authenticated-orcid":false,"given":"Jos\u00e9 Maria","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Ascen\u00e7\u00e3o de","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4050-1729","authenticated-orcid":false,"given":"Leonardo Sara da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6986-8535","authenticated-orcid":false,"given":"Lilia Nigro","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4823-9673","authenticated-orcid":false,"given":"Louis Nakayama","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano Moreira","family":"Baracioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds Alberto de Oliveira","family":"Dallan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8122-6647","authenticated-orcid":false,"given":"Luis Augusto Palma","family":"Dallan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Alberto Piva e","family":"Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3142-7336","authenticated-orcid":false,"given":"Luiz Carlos","family":"Bodanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9320-7999","authenticated-orcid":false,"given":"Luiz Eduardo Fonteles","family":"Ritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6014-5533","authenticated-orcid":false,"given":"Manoel Fernandes","family":"Canesin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Bueno da Silva","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4286-8559","authenticated-orcid":false,"given":"Marcelo","family":"Franken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Jos\u00e9 Gomes","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9413-3792","authenticated-orcid":false,"suffix":"J\u00fanior","given":"M\u00facio Tavares de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1382-6656","authenticated-orcid":false,"suffix":"Filho","given":"Nivaldo Menezes","family":"Filgueiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0032-0461","authenticated-orcid":false,"given":"Oscar Pereira","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-2685","authenticated-orcid":false,"given":"Ot\u00e1vio Rizzi","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Ernesto","family":"Le\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Roberto Ferreira","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Rog\u00e9rio","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Neto","given":"Pedro Alves","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7427-3237","authenticated-orcid":false,"given":"Pedro Silvio","family":"Farsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Reb\u00ealo C.","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Jorge","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-129X","authenticated-orcid":false,"given":"Renato Abdala Karam","family":"Kalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-5794","authenticated-orcid":false,"given":"Roberto","family":"Esporcatte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Luiz","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1838-9902","authenticated-orcid":false,"given":"Roberto Rocha Corr\u00eaa Veiga","family":"Giraldez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7050-8967","authenticated-orcid":false,"given":"Romeu S\u00e9rgio","family":"Meneghelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo de Souza Le\u00e3o","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui Fernando","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0448-8667","authenticated-orcid":false,"given":"Sandra Nivea dos Reis Saraiva","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0525-0506","authenticated-orcid":false,"given":"Talia Falc\u00e3o","family":"Dal\u00e7\u00f3quio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0732-9920","authenticated-orcid":false,"given":"Viviana de Mello Guzzo","family":"Lemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3751-0728","authenticated-orcid":false,"given":"William Azem","family":"Chalela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-6754","authenticated-orcid":false,"suffix":"J\u00fanior","given":"Wilson","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22636","reference":[{"issue":"2","key":"key20210719142633_B1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/hrt.2003.027599","article-title":"The health care burden of acute chest pain","volume":"91","author":"Goodacre","year":"2005","unstructured":"1. Goodacre S, Cross E, Arnold J, Angelini K, Capewell S, Nicholl J. The health care burden of acute chest pain. Heart. 2005;91(2):229-30.","journal-title":"Heart"},{"issue":"3","key":"key20210719142633_B2","first-page":"170","article-title":"Acute Coronary Syndrome: Diagnostic Evaluation","volume":"95","author":"Barstow","year":"2017","unstructured":"2. Barstow C, Rice M, McDivitt JD. Acute Coronary Syndrome: Diagnostic Evaluation. Am Fam Physician. 2017;95(3):170-7.","journal-title":"Am Fam Physician"},{"issue":"3","key":"key20210719142633_B3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/HPC.0000000000000151","article-title":"Continuum of Care for Acute Coronary Syndrome: Optimizing Treatment for ST-Elevation Myocardial Infarction and Non-St-Elevation Acute Coronary Syndrome","volume":"17","author":"Gibler","year":"2018","unstructured":"3. Gibler WB, Racadio JM, Hirsch AL, Roat TW. Continuum of Care for Acute Coronary Syndrome: Optimizing Treatment for ST-Elevation Myocardial Infarction and Non-St-Elevation Acute Coronary Syndrome. Crit Pathw Cardiol. 2018;17(3):114-38.","journal-title":"Crit Pathw Cardiol"},{"issue":"3","key":"key20210719142633_B4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"40","author":"Thygesen","year":"2019","unstructured":"4. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-69.","journal-title":"Eur Heart J."},{"issue":"10","key":"key20210719142633_B5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.114.011201","article-title":"Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries","volume":"131","author":"Pasupathy","year":"2015","unstructured":"5. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation. 2015;131(10):861-70. Erratum in: Circulation. 2015;131(19):e475.","journal-title":"Circulation"},{"issue":"1","key":"key20210719142633_B6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/2048872618782414","article-title":"Editor's Choice-Pathophysiology, diagnosis and management of MINOCA: an update Eur Heart J","volume":"8","author":"Scalone","year":"2019","unstructured":"6. Scalone G, Niccoli G, Crea F. Editor's Choice-Pathophysiology, diagnosis and management of MINOCA: an update. Eur Heart J. Acute Cardiovasc Care. 2019;8(1):54-62.","journal-title":"Acute Cardiovasc Care"},{"issue":"Suppl E","key":"key20210719142633_B7","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1093\/eurheartj\/suaa057","article-title":"Myocardial infarction with non-obstructive coronary arteries: what is the prognosis?","volume":"22","author":"Niccoli","year":"2020","unstructured":"7. Niccoli G, Camici PG. Myocardial infarction with non-obstructive coronary arteries: what is the prognosis?. Eur Heart J Suppl. 2020;22(Suppl E):E40-5.","journal-title":"Eur Heart J Suppl"},{"issue":"18","key":"key20210719142633_B8","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1161\/CIR.0000000000000670","article-title":"Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association","volume":"139","author":"Tamis-Holland","year":"2019","unstructured":"8. Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM, et al. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019;139(18):e891-e908.","journal-title":"Circulation"},{"issue":"3","key":"key20210719142633_B9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/CIRCINTERVENTIONS.113.000606","article-title":"Prognosis of patients with non-ST- segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial","volume":"7","author":"Planer","year":"2014","unstructured":"9. Planer D, Mehran R, Ohman EM, White HD, Newman JD, Xu K, et al. Prognosis of patients with non-ST- segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circ Cardiovasc Interv. 2014;7(3):285-93.","journal-title":"Circ Cardiovasc Interv"},{"issue":"16","key":"key20210719142633_B10","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1161\/CIRCULATIONAHA.117.027666","article-title":"Myocardial Infarction With Nonobstructive Coronary Arteries (MINOCA): The Past, Present, and Future Management","volume":"135","author":"Pasupathy","year":"2017","unstructured":"10. Pasupathy S, Tavella R, Beltrame JF. Myocardial Infarction With Nonobstructive Coronary Arteries (MINOCA): The Past, Present, and Future Management. Circulation. 2017 Apr 18;135(16):1490-3.","journal-title":"Circulation"},{"issue":"4","key":"key20210719142633_B11","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/01.CIR.89.4.1545","article-title":"Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia","volume":"89","year":"1994","unstructured":"11. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation. 1994 Apr;89(4):1545-56.","journal-title":"Circulation"},{"issue":"12","key":"key20210719142633_B12","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1161\/01.CIR.97.12.1195","article-title":"Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction","volume":"97","author":"Theroux","year":"1998","unstructured":"12. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1998 Mar 31;97(12):1195-206.","journal-title":"Circulation"},{"issue":"1","key":"key20210719142633_B13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0735-1097(98)00553-1","article-title":"Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?","volume":"33","author":"Zaacks","year":"1999","unstructured":"13. Zaacks SM, Liebson PR, Calvin JE, Parrillo JE, Klein LW. Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J Am Coll Cardiol. 1999 Jan;33(1):107-18.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"key20210719142633_B14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0002-8703(98)70209-1","article-title":"Clinical predictors easily obtained at presentation predict resource utilization in unstable angina","volume":"136","author":"Calvin","year":"1998","unstructured":"14. Calvin JE, Klein LW, VandenBerg BJ, Meyer P, Ramirez-Morgen LM, Parrillo JE. Clinical predictors easily obtained at presentation predict resource utilization in unstable angina. Am Heart J. 1998 Sep;136(3):373-81.","journal-title":"Am Heart J"},{"issue":"2","key":"key20210719142633_B15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0733-8651(05)70072-2","article-title":"The health care burden of unstable angina","volume":"17","author":"Kong","year":"1999","unstructured":"15. Kong DF, Blazing MA, O\u2019Connor CM. The health care burden of unstable angina. Cardiol Clin. 1999 May;17(2):247-61.","journal-title":"Cardiol Clin"},{"issue":"3","key":"key20210719142633_B16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","unstructured":"16. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315.","journal-title":"Eur Heart J"},{"issue":"9963","key":"key20210719142633_B17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"Naghavi","year":"2015","unstructured":"17. Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al; GBD 2013Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71.","journal-title":"Lancet"},{"key":"key20210719142633_B18","author":"Brasil. Minist\u00e9rio da Sa\u00fade","unstructured":"18. Brasil. Minist\u00e9rio da Sa\u00fade. Informa\u00e7\u00e3o em sa\u00fade: Estat\u00edsticas vitais. [Citado em 2020 fev 26]. Dispon\u00edvel em: http:\/\/datasus.saude.gov.br\/).","journal-title":"Informa\u00e7\u00e3o em sa\u00fade: Estat\u00edsticas vitais"},{"key":"key20210719142633_B19","first-page":"qcz045","article-title":"Performance of acute coronary syndrome approaches in Brazil. A report from the BRACE (Brazilian Registry in Acute Coronary syndromEs)","author":"Franken","year":"2019","unstructured":"19. Franken M, Giugliano RP, Goodman SG, Baracioloi L, Godoy LC, Furtado RHM, et al. Performance of acute coronary syndrome approaches in Brazil. A report from the BRACE (Brazilian Registry in Acute Coronary syndromEs) [published online ahead of print, 2019 Aug 10]. Eur Heart J Qual Care Clin Outcomes. 2019;qcz045.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"21","key":"key20210719142633_B20","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy","volume":"368","author":"Libby","year":"2013","unstructured":"20. Libby P. Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy. N Engl J Med. 2013;368(21):2004-13.","journal-title":"N Engl J Med"},{"issue":"14","key":"key20210719142633_B21","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jacc.2015.02.032","article-title":"Evolving therapies for myocardial ischemia\/reperfusion injury","volume":"65","author":"Ib\u00e1\u00f1ez","year":"2015","unstructured":"21. Ib\u00e1\u00f1ez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia\/reperfusion injury. J Am Coll Cardiol.2015; 65(14):1454-71.","journal-title":"J Am Coll Cardiol"},{"issue":"suppl I","key":"key20210719142633_B22","first-page":"I-1","article-title":"The National Heart, Lung and Blood Institute Coronary Artery Surgery Study: historical background, design, methods, the registry, the randomized trial, clinical database","volume":"63","author":"The Principal Investigators of CASS and Their Associates","year":"1981","unstructured":"22. The Principal Investigators of CASS and Their Associates. The National Heart, Lung and Blood Institute Coronary Artery Surgery Study: historical background, design, methods, the registry, the randomized trial, clinical database. Circulation. 1981;63(suppl I):I-1-I-81.","journal-title":"Circulation"},{"issue":"14","key":"key20210719142633_B23","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jama.1996.03530380046030","article-title":"Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry","volume":"275","author":"Stone","year":"1996","unstructured":"23. Stone PH, Thompson B, Anderson HV, Kronenberg MW, Gibson RS, Rogers WJ, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA. 1996 Apr 10;275(14):1104-12.","journal-title":"JAMA"},{"key":"key20210719142633_B24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2015.06.119","article-title":"Influence of proven oral therapies in the very old with acute coronary syndromes: A 15 year experience","volume":"198","author":"Nicolau","year":"2015","unstructured":"24. Nicolau JC, Franci A, Barbosa CJ, Baracioli LM, Franken M, Furtado RH, et al. Influence of proven oral therapies in the very old with acute coronary syndromes: A 15 year experience. Int J Cardiol. 2015 Nov 1;198:213-5.","journal-title":"Int J Cardiol"},{"issue":"4","key":"key20210719142633_B25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0002-9149(97)89383-6","article-title":"Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry)","volume":"77","author":"Kleiman","year":"1996","unstructured":"25. Kleiman NS, Anderson HV, Rogers WJ, Theroux P, Thompson B, Stone PH. Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry). Am J Cardiol. 1996 Feb 1;77(4):227-31.","journal-title":"Am J Cardiol"},{"issue":"5","key":"key20210719142633_B26","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/0735-1097(95)00299-5","article-title":"Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the \u201csmoker's paradox\u201d from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries","volume":"26","author":"Barbash","year":"1995","unstructured":"26. Barbash GI, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowski Z, et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the \u201csmoker's paradox\u201d from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995 Nov 1;26(5):1222-9.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20210719142633_B27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1161\/01.CIR.87.1.53","article-title":"Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator\/Streptokinase Mortality Trial","volume":"87","author":"Barbash","year":"1993","unstructured":"27. Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, et al. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator\/Streptokinase Mortality Trial. Circulation. 1993 Jan;87(1):53-8.","journal-title":"Circulation"},{"issue":"7","key":"key20210719142633_B28","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non-ST elevation MI: A method for prognostication and therapeutic decision making","volume":"284","author":"Antman","year":"2000","unstructured":"28. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina\/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000 Aug 16;284(7):835-42.","journal-title":"JAMA"},{"issue":"1","key":"key20210719142633_B29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/01.CIR.90.1.613","article-title":"Diagnosing and managing unstable angina. Agency for Health Care Policy and Research","volume":"90","author":"Braunwald","year":"1994","unstructured":"29. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation. 1994 Jul;90(1):613-22.","journal-title":"Circulation"},{"issue":"2","key":"key20210719142633_B30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJM200001133420207","article-title":"Unstable angina pectoris","volume":"342","author":"Yeghiazarians","year":"2000","unstructured":"30. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med. 2000 Jan 13;342(2):101-14.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20210719142633_B31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(99)00416-7","article-title":"Redefining medical treatment in the management of unstable angina","volume":"108","author":"Braunwald","year":"2000","unstructured":"31. Braunwald E, Califf RM, Cannon CP, Fox KA, Fuster V, Gibler WB, et al. Redefining medical treatment in the management of unstable angina. Am J Med. 2000 Jan;108(1):41-53.","journal-title":"Am J Med"},{"issue":"5","key":"key20210719142633_B32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0002-9343(91)90185-Z","article-title":"Clinical and angiographic features and prognostic significance of early postinfarction angina with and without electrocardiographic signs of transient ischemia","volume":"91","author":"Bosch","year":"1991","unstructured":"32. Bosch X, Theroux P, Pelletier GB, Sanz G, Roy D, Waters D. Clinical and angiographic features and prognostic significance of early postinfarction angina with and without electrocardiographic signs of transient ischemia. Am J Med. 1991 Nov;91(5):493-501.","journal-title":"Am J Med"},{"issue":"4","key":"key20210719142633_B33","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0735-1097(87)80267-X","article-title":"Silent ischemia predicts infarction and death during 2 year follow-up of unstable angina","volume":"10","author":"Gottlieb","year":"1987","unstructured":"33. Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED, Gerstenblith G. Silent ischemia predicts infarction and death during 2 year follow-up of unstable angina. J Am Coll Cardiol. 1987 Oct;10(4):756-60.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"key20210719142633_B34","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1161\/01.CIR.98.18.1860","article-title":"Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators","volume":"98","author":"Armstrong","year":"1998","unstructured":"34. Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB, Betriu A, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation. 1998 Nov 3;98(18):1860-8.","journal-title":"Circulation"},{"issue":"1","key":"key20210719142633_B35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0735-1097(97)00160-5","article-title":"The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia","volume":"30","author":"Cannon","year":"1997","unstructured":"35. Cannon CP, McCabe CH, Stone PH, Rogers WJ, Schactman M, Thompson BW, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol. 1997 Jul;30(1):133-40.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20210719142633_B36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/0003-4819-105-2-221","article-title":"Serum enzyme assays in the diagnosis of acute myocardial infarction. Recommendations based on a quantitative analysis","volume":"105","author":"Lee","year":"1986","unstructured":"36. Lee TH, Goldman L. Serum enzyme assays in the diagnosis of acute myocardial infarction. Recommendations based on a quantitative analysis. Ann Intern Med. 1986 Aug;105(2):221-33.","journal-title":"Ann Intern Med"},{"issue":"18","key":"key20210719142633_B37","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1161\/01.CIR.98.18.1853","article-title":"Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators","volume":"98","author":"Newby","year":"1998","unstructured":"37. Newby LK, Christenson RH, Ohman EM, Armstrong PW, Thompson TD, Lee KL, et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation. 1998 Nov 3;98(18):1853-9.","journal-title":"Circulation"},{"issue":"17","key":"key20210719142633_B38","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1161\/CIR.0b013e3181ec61df","article-title":"Testing of low-risk patients presenting to the emergency department with chest pain. A Scientific Statement From the American Heart Association","volume":"122","author":"Amsterdam","year":"2010","unstructured":"38. Amsterdam EA, Kirk JD, Bluemke DA, Diercks DE, Farkouh ME, Garvey JE, et al. Testing of low-risk patients presenting to the emergency department with chest pain. A Scientific Statement From the American Heart Association. Circulation. 2010;122(17):1756-776.","journal-title":"Circulation"},{"issue":"18","key":"key20210719142633_B39","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJM199610313351801","article-title":"Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators","volume":"335","author":"Ohman","year":"1996","unstructured":"39. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med. 1996 Oct 31;335(18):1333-41.","journal-title":"N Engl J Med"},{"issue":"11","key":"key20210719142633_B40","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1161\/01.CIR.102.11.1216","article-title":"It's time for a change to a troponin standard","volume":"102","author":"Jaffe","year":"2000","unstructured":"40. Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, et al. It's time for a change to a troponin standard. Circulation. 2000 Sep 12;102(11):1216-20.","journal-title":"Circulation"},{"issue":"9","key":"key20210719142633_B41","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJMoa0900428","article-title":"Early diagnosis of myocardial infarction with sensitive cardiac troponin assays","volume":"361","author":"Reichlin","year":"2009","unstructured":"41. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361(9):858-67.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20210719142633_B42","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1373\/clinchem.2009.132654","article-title":"Analytical validation of a high-sensitivity cardiac troponin T assay","volume":"56","author":"Giannitsis","year":"2010","unstructured":"42. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56(2):254-61.","journal-title":"Clin Chem"},{"issue":"9","key":"key20210719142633_B43","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/eurheartj\/eht530","article-title":"Biomarkers and acute coronary syndromes: an update","volume":"35","author":"Mueller","year":"2014","unstructured":"43. Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J. 2014;35(9):552\u20136.","journal-title":"Eur Heart J"},{"issue":"8","key":"key20210719142633_B44","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrcardio.2017.48","article-title":"High-sensitivity assays for troponin in patients with cardiac disease","volume":"14","author":"Westermann","year":"2017","unstructured":"44. Westermann D, Neumann J, S\u00f6rensen N,Blankenberg S. High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol.2017;14(8):472-83.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"key20210719142633_B45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/2048872619861911","article-title":"RAPID-CPU: a prospective study on implementation of the ESC 0\/1-hour algorithm and safety of discharge after rule-out of myocardial infarction","volume":"9","author":"Stoyanov","year":"2020","unstructured":"45. Stoyanov KM, Hund H, Biener M,Gandowitz J, Riedle C, Lohr J, et al. RAPID-CPU: a prospective study on implementation of the ESC 0\/1-hour algorithm and safety of discharge after rule-out of myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2020;9(1):39-51.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"17","key":"key20210719142633_B46","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/CIRCULATIONAHA.116.025661","article-title":"Direct Comparison of 4 Very Early Rule-Out Strategies for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin I","volume":"135","author":"Boeddinghaus","year":"2017","unstructured":"46. Boeddinghaus J, Nestelberger T, Twerenbold R, Wildi K, Badertscher P, Cupa J, et al. Direct Comparison of 4 Very Early Rule-Out Strategies for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin I. Circulation. 2017 Apr 25;135(17):1597-11.","journal-title":"Circulation"},{"issue":"9","key":"key20210719142633_B47","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/clinchem\/41.9.1266","article-title":"Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction","volume":"41","author":"Mair","year":"1995","unstructured":"47. Mair J, Morandell D, Genser N, Lechleitner P, Dienstl F, Puschendorf B. Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction. Clin Chem. 1995 Sep;41(9):1266-72.","journal-title":"Clin Chem"},{"issue":"3","key":"key20210719142633_B48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.amjcard.2007.08.037","article-title":"Comparison of MB fraction of creatine kinase mass and troponin I serum levels with necropsy findings in acute myocardial infarction","volume":"101","author":"Costa","year":"2008","unstructured":"48. Costa TN, Strunz CM, Nicolau JC, Gutierrez PS. Comparison of MB fraction of creatine kinase mass and troponin I serum levels with necropsy findings in acute myocardial infarction. Am J Cardiol. 2008 Feb 1;101(3):311-4.","journal-title":"Am J Cardiol"},{"issue":"2","key":"key20210719142633_B49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1373\/clinchem.2003.026708","article-title":"Rates of positive cardiac troponin I and creatine kinase MB mass among Patients Hospitalized for Suspected Acute Coronary Syndromes","volume":"50","author":"Lin","year":"2004","unstructured":"49. Lin JC, Apple FS, Murakami M,Luepker RV. Rates of positive cardiac troponin I and creatine kinase MB mass among Patients Hospitalized for Suspected Acute Coronary Syndromes. Clin Chem. 2004;50(2):333\u20138.","journal-title":"Clin Chem"},{"issue":"2","key":"key20210719142633_B50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0735-1097(02)01968-X","article-title":"Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain","volume":"40","author":"Amsterdam","year":"2002","unstructured":"50. Amsterdam EA, Kirk JD, Diercks DB, Lewis WR, Turnipseed SD. Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain. J Am Coll Cardiol. 2002;40(2):251-6. 165.","journal-title":"J Am Coll Cardiol"},{"issue":"5 Suppl 1","key":"key20210719142633_B51","first-page":"1","article-title":"Sociedade Brasileira de Cardiologia. III Diretrizes da Sociedade Brasileira de Cardiologia sobre teste ergom\u00e9trico","volume":"95","author":"Meneghelo","year":"2010","unstructured":"51. Meneghelo RS, Ara\u00fajo CG, Stein R, Mastrocolla LE, Albuquerque PF, Serra SM, et al; Sociedade Brasileira de Cardiologia. III Diretrizes da Sociedade Brasileira de Cardiologia sobre teste ergom\u00e9trico. Arq Bras Cardiol. 2010;95(5 Suppl 1):1-26.","journal-title":"Arq Bras Cardiol"},{"issue":"11","key":"key20210719142633_B52","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0002-9149(90)90143-O","article-title":"Usefulness of two-dimensional echocardiography for immediate detection of myocardial ischemia in the emergency room","volume":"65","author":"Peels","year":"1990","unstructured":"52. Peels CH, Visser CA, Kupper AJ, Visser FC, Roos JP. Usefulness of two-dimensional echocardiography for immediate detection of myocardial ischemia in the emergency room. Am J Cardiol. 1990 Mar 15;65(11):687-91.","journal-title":"Am J Cardiol"},{"issue":"4","key":"key20210719142633_B53","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/01.CIR.84.4.1615","article-title":"Importance of two-dimensional echocardiographic assessment of left ventricular systolic function in patients presenting to the emergency room with cardiac-related symptoms","volume":"84","author":"Sabia","year":"1991","unstructured":"53. Sabia P, Abbott RD, Afrookteh A, Keller MW, Touchstone DA, Kaul S. Importance of two-dimensional echocardiographic assessment of left ventricular systolic function in patients presenting to the emergency room with cardiac-related symptoms. Circulation. 1991 Oct;84(4):1615-24.","journal-title":"Circulation"},{"issue":"18","key":"key20210719142633_B54","doi-asserted-by":"crossref","first-page":"17H","DOI":"10.1016\/0002-9149(90)90571-H","article-title":"Role of echocardiography in acute myocardial infarction","volume":"66","author":"Feigenbaum","year":"1990","unstructured":"54. Feigenbaum H. Role of echocardiography in acute myocardial infarction. Am J Cardiol. 1990 Nov 20;66(18):17H-22H.","journal-title":"Am J Cardiol"},{"issue":"3","key":"key20210719142633_B55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0894-7317(88)80072-5","article-title":"The case for echocardiography in acute myocardial infarction","volume":"1","author":"Parisi","year":"1988","unstructured":"55. Parisi AF. The case for echocardiography in acute myocardial infarction. J Am Soc Echocardiogr. 1988 May;1(3):173-8.","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"key20210719142633_B56","first-page":"247","article-title":"The role of two-dimensional echocardiography in coronary artery disease: a critical appraisal","volume":"57","author":"Reeder","year":"1982","unstructured":"56. Reeder GS, Seward JB, Tajik AJ. The role of two-dimensional echocardiography in coronary artery disease: a critical appraisal. Mayo Clin Proc. 1982 Apr;57(4):247-58.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"key20210719142633_B57","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/0002-9149(82)90034-0","article-title":"Value of early two dimensional echocardiography in patients with acute myocardial infarction","volume":"49","author":"Gibson","year":"1982","unstructured":"57. Gibson RS, Bishop HL, Stamm RB, Crampton RS, Beller GA, Martin RP. Value of early two dimensional echocardiography in patients with acute myocardial infarction. Am J Cardiol. 1982 Apr 1;49(5):1110-9.","journal-title":"Am J Cardiol"},{"issue":"5","key":"key20210719142633_B58","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/0002-9149(81)90207-1","article-title":"Detection and quantification of acute, isolated myocardial infarction by two dimensional echocardiography","volume":"47","author":"Visser","year":"1981","unstructured":"58. Visser CA, Lie KI, Kan G, Meltzer R, Durrer D. Detection and quantification of acute, isolated myocardial infarction by two dimensional echocardiography. Am J Cardiol. 1981 May;47(5):1020-5.","journal-title":"Am J Cardiol"},{"issue":"6","key":"key20210719142633_B59","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/01.CIR.61.6.1113","article-title":"Cross-sectional echocardiographic analysis of the extent of left ventricular asynergy in acute myocardial infarction","volume":"61","author":"Heger","year":"1980","unstructured":"59. Heger JJ, Weyman AE, Wann LS, Rogers EW, Dillon JC, Feigenbaum H. Cross-sectional echocardiographic analysis of the extent of left ventricular asynergy in acute myocardial infarction. Circulation. 1980 Jun;61(6):1113-8.","journal-title":"Circulation"},{"issue":"5","key":"key20210719142633_B60","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0735-1097(98)90056-0","article-title":"Exercise echocardiography: detection of coronary artery disease in patients with normal left ventricular wall motion at rest","volume":"11","author":"Ryan","year":"1988","unstructured":"60. Ryan T, Vasey CG, Presti CF, O\u2019Donnell JA, Feigenbaum H, Armstrong WF. Exercise echocardiography: detection of coronary artery disease in patients with normal left ventricular wall motion at rest. J Am Coll Cardiol. 1988 May;11(5):993-9.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20210719142633_B61","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-8703(90)90159-U","article-title":"Prognostic value of a normal exercise echocardiogram","volume":"120","author":"Sawada","year":"1990","unstructured":"61. Sawada SG, Ryan T, Conley MJ, Corya BC, Feigenbaum H, Armstrong WF. Prognostic value of a normal exercise echocardiogram. Am Heart J. 1990 Jul;120(1):49-55.","journal-title":"Am Heart J"},{"issue":"6","key":"key20210719142633_B62","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1161\/01.CIR.95.6.1686","article-title":"ACC\/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography","volume":"95","author":"Cheitlin","year":"1997","unstructured":"62. Cheitlin MD, Alpert JS, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, et al. ACC\/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation. 1997 Mar 18;95(6):1686-744.","journal-title":"Circulation"},{"issue":"23","key":"key20210719142633_B63","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2013.02.061","article-title":"Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction","volume":"61","author":"Ersb\u00f8ll","year":"2013","unstructured":"63. Ersb\u00f8ll M, Valeur N, Mogensen UM, Andersen MJ, M\u00f8ller JE, Velazquez EJ, Hassager C,et al. Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2013 Jun 11;61(23):2365-73.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"key20210719142633_B64","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0002-9149(98)00462-7","article-title":"Risk stratification of patients with medically treated unstable angina using exercise echocardiography","volume":"82","author":"Lin","year":"1998","unstructured":"64. Lin SS, Lauer MS, Marwick TH. Risk stratification of patients with medically treated unstable angina using exercise echocardiography. Am J Cardiol. 1998 Sep 15;82(6):720-4.","journal-title":"Am J Cardiol"},{"issue":"10","key":"key20210719142633_B65","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S0002-9149(98)00615-8","article-title":"Utility of stress echocardiography in the triage of patients with atypical chest pain from the emergency department","volume":"82","author":"Colon","year":"1998","unstructured":"65. Colon PJ, III, Guarisco JS, Murgo J, Cheirif J. Utility of stress echocardiography in the triage of patients with atypical chest pain from the emergency department. Am J Cardiol. 1998 Nov 15;82(10):1282-4, A10.","journal-title":"Am J Cardiol"},{"issue":"3","key":"key20210719142633_B66","first-page":"294","article-title":"Stratifying the risk in unstable angina with dobutamine stress echocardiography","volume":"87","author":"Markman","year":"2006","unstructured":"66. Markman Filho B, Almeida MC, Markman M, Chaves A, Moretti M,Ramires JA, Cesar LA. Stratifying the risk in unstable angina with dobutamine stress echocardiography. Arq Bras Cardiol. 2006; 87(3):294-9.","journal-title":"Arq Bras Cardiol"},{"issue":"2","key":"key20210719142633_B67","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0735-1097(97)00164-2","article-title":"Relevance of increased lung thallium uptake on stress imaging in patients with unstable angina and non-Q wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI)-IIIB Study","volume":"30","author":"Jain","year":"1997","unstructured":"67. Jain D, Thompson B, Wackers FJ, Zaret BL. Relevance of increased lung thallium uptake on stress imaging in patients with unstable angina and non-Q wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI)-IIIB Study. J Am Coll Cardiol. 1997 Aug;30(2):421-9.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20210719142633_B68","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.CIR.96.1.137","article-title":"Cardiac imaging for risk stratification with dobutamine-atropine stress testing in patients with chest pain. Echocardiography, perfusion scintigraphy, or both?","volume":"96","author":"Geleijnse","year":"1997","unstructured":"68. Geleijnse ML, Elhendy A, van Domburg RT, Cornel JH, Rambaldi R, Salustri A, et al. Cardiac imaging for risk stratification with dobutamine-atropine stress testing in patients with chest pain. Echocardiography, perfusion scintigraphy, or both? Circulation. 1997 Jul 1;96(1):137-47.","journal-title":"Circulation"},{"issue":"4","key":"key20210719142633_B69","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0735-1097(97)00264-7","article-title":"Value of acute rest sestamibi perfusion imaging for evaluation of patients admitted to the emergency department with chest pain","volume":"30","author":"Kontos","year":"1997","unstructured":"69. Kontos MC, Jesse RL, Schmidt KL, Ornato JP, Tatum JL. Value of acute rest sestamibi perfusion imaging for evaluation of patients admitted to the emergency department with chest pain. J Am Coll Cardiol. 1997 Oct;30(4):976-82.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"key20210719142633_B70","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.nuclcard.2004.05.007","article-title":"Acute resting myocardial perfusion imaging in patients with diabetes mellitus: results from the Emergency Room Assessment of Sestamibi for Evaluation of Chest Pain (ERASE Chest Pain) trial","volume":"11","author":"Kapetanopoulos","year":"2004","unstructured":"70. Kapetanopoulos A, Heller GV, Selker HP, Ruthazer R, Beshansky JR, Feldman JA, et al. Acute resting myocardial perfusion imaging in patients with diabetes mellitus: results from the Emergency Room Assessment of Sestamibi for Evaluation of Chest Pain (ERASE Chest Pain) trial. J Nucl Cardiol. 2004 Sep;11(5):570-7.","journal-title":"J Nucl Cardiol"},{"issue":"22","key":"key20210719142633_B71","first-page":"e561","article-title":"ACCF\/ASNC\/ACR\/AHA\/ASE\/SCCT\/SCMR\/SNM 2009 appropriate use criteria for cardiac radionuclide imaging","volume":"119","author":"Hendel","year":"2009","unstructured":"71. Hendel RC, Berman DS, Di Carli MF, Heidenreich PA, Henkin RE, Pellikka PA, Pohost GM,et al. ACCF\/ASNC\/ACR\/AHA\/ASE\/SCCT\/SCMR\/SNM 2009 appropriate use criteria for cardiac radionuclide imaging. Circulation. 2009 Jun 9;119(22):e561-87;","journal-title":"Circulation"},{"issue":"7","key":"key20210719142633_B72","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jacc.2003.08.011","article-title":"American College of Cardiology; American Heart Association; American Society for Nuclear Cardiology. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Society for Nuclear Cardiology. ACC\/AHA\/ASNC guidelines for the clinical use of cardiac radionuclide imaging: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/ASNC Committee to Revise the 1995 Guidelines for the clinical use of cardiac radionuclide imaging)","volume":"42","author":"Klocke","year":"2003","unstructured":"72. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al; American College of Cardiology; American Heart Association; American Society for Nuclear Cardiology. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Society for Nuclear Cardiology. ACC\/AHA\/ASNC guidelines for the clinical use of cardiac radionuclide imaging: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/ASNC Committee to Revise the 1995 Guidelines for the clinical use of cardiac radionuclide imaging). J Am Coll Cardiol. 2003;42(7):1318-33.","journal-title":"J Am Coll Cardiol"},{"issue":"Spec 3","key":"key20210719142633_B73","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1259\/bjr\/14625142","article-title":"Myocardial perfusion scintigraphy: past, present and future","volume":"84","author":"Notghi","year":"2011","unstructured":"73. Notghi A, Low CS. Myocardial perfusion scintigraphy: past, present and future. Br J Radiol.2011;84(Spec 3):S229-36.","journal-title":"Br J Radiol"},{"issue":"2","key":"key20210719142633_B74","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1067\/mnc.2002.122630","article-title":"American Society of Nuclear Cardiology position statement on radionuclide imaging in patients with suspected acute ischemic syndromes in the emergency department or chest pain center","volume":"9","author":"Wackers","year":"2002","unstructured":"74. Wackers FJ, Brown KA, Heller GV, Kontos MC, Tatum JL, Udelson JE, et al. American Society of Nuclear Cardiology position statement on radionuclide imaging in patients with suspected acute ischemic syndromes in the emergency department or chest pain center. J Nucl Cardiol. 2002;9(2):246-50.","journal-title":"J Nucl Cardiol"},{"issue":"21","key":"key20210719142633_B75","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2008.07.031","article-title":"iagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial","volume":"52","author":"Budoff","year":"2008","unstructured":"75. Budoff MJ, Dowe D, Jollis JG,Gitter M, Sutherland J, Halamert E, et al. iagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. J Am Coll Cardiol. 2008;52(21):1724-32.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"key20210719142633_B76","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa0806576","article-title":"Diagnostic performance of coronary angiography by 64-row CT","volume":"359","author":"Miller","year":"2008","unstructured":"76. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Gottlieb NH, Clouse ME, et al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 2008;359(22):2324-36.","journal-title":"N Engl J Med"},{"issue":"25","key":"key20210719142633_B77","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2008.08.058","article-title":"Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study","volume":"52","author":"Meijboom","year":"2008","unstructured":"77. Meijboom WB, Meijs MF, Schuijf JD, Cramer MJ, Mollet NR, van Mieghem CA, et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol. 2008;52(25):2135-44.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"key20210719142633_B78","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1161\/CIRCULATIONAHA.116.024360","article-title":"PROMISE Investigators. Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain)","volume":"135","author":"Hoffmann","year":"2017","unstructured":"78. Hoffmann U, Ferencik M, Udelson JE, Picard MH, Truong QA, Patel MR, et al.; PROMISE Investigators. Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation. 2017;135(24):2320-32.","journal-title":"Circulation"},{"issue":"41","key":"key20210719142633_B79","first-page":"3689","article-title":"Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease","volume":"39","author":"Collet","year":"2018","unstructured":"79. Collet C, Onuma Y, Andreini D, Sonck J, Pompilio G, Mushtaq S,et al. Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease. Eur Heart J. 2018 Nov 1;39(41):3689-98.","journal-title":"Eur Heart J"},{"issue":"14","key":"key20210719142633_B80","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.jacc.2011.03.068","article-title":"The CT-STAT (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment) trial","volume":"58","author":"Goldstein","year":"2011","unstructured":"80. Goldstein JA, Chinnaiyan KM, Abidov A, Achenbach S, Berman DS, Hayes SW,et al. The CT-STAT (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment) trial. J Am Coll Cardiol. 2011;58(14):1414-22.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"key20210719142633_B81","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1201163","article-title":"CT angiography for safe discharge of patients with possible acute coronary syndromes","volume":"366","author":"Litt","year":"2012","unstructured":"81. Litt HI, Gatsonis C, Snyder B, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. N Engl J Med. 2012;366(15):1393-403.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20210719142633_B82","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1201161","article-title":"Coronary CT angiography versus standard evaluation in acute chest pain","volume":"367","author":"Hoffmann","year":"2012","unstructured":"82. Hoffmann U, Truong QA, Schoenfeld DA, Chou ET, Woodard PK, Nagurney JT, et al. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med 2012;367(4):299-308.","journal-title":"N Engl J Med"},{"issue":"8","key":"key20210719142633_B83","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jacc.2012.11.061","article-title":"Outcomes After Coronary Computed Tomography Angiography in the Emergency Department: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials","volume":"61","author":"Hulten","year":"2013","unstructured":"83. Hulten E, Pickett C, Bittencourt MS,Villines Tc, Petrillo S, Di Carlo MF, et al. Outcomes After Coronary Computed Tomography Angiography in the Emergency Department: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. J Am Coll Cardiol. 2013;61(8):880-92.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"key20210719142633_B84","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.acra.2009.01.014","article-title":"Triple rule-out CT in patients with suspicion of acute pulmonary embolism: findings and accuracy","volume":"16","author":"Schertler","year":"2009","unstructured":"84. Schertler T, Frauenfelder T, Stolzmann P, Scheffel H, Desbiolles L, Marincek B, Kaplan V, Kucher N, Alkadhi H. Triple rule-out CT in patients with suspicion of acute pulmonary embolism: findings and accuracy. Acad Radiol. 2009 Jun;16(6):708-17.","journal-title":"Acad Radiol"},{"issue":"2","key":"key20210719142633_B85","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ajem.2009.09.002","article-title":"A time and imaging cost analysis of low-risk ED observation patients: a conservative 64-section computed tomography coronary angiography \u201ctriple rule-out\u201d compared to nuclear stress test strategy","volume":"29","author":"Takakuwa","year":"2011","unstructured":"85. Takakuwa KM, Halpern EJ, Shofer FS. A time and imaging cost analysis of low-risk ED observation patients: a conservative 64-section computed tomography coronary angiography \u201ctriple rule-out\u201d compared to nuclear stress test strategy. Am J Emerg Med. 2011 Feb;29(2):187-95.","journal-title":"Am J Emerg Med"},{"issue":"6 Suppl 3","key":"key20210719142633_B86","first-page":"1","article-title":"II Guidelines on Cardiovascular Magnetic Resonance and Computed Tomography of the Brazilian Society of Cardiology and the Brazilian College of Radiology","volume":"103","author":"Sara","year":"2014","unstructured":"86. Sara L, Szarf G, Tachibana A, Shiozaki AA, Villa AV, de Oliveira AC, de Albuquerque AS, et al. II Guidelines on Cardiovascular Magnetic Resonance and Computed Tomography of the Brazilian Society of Cardiology and the Brazilian College of Radiology. Arq Bras Cardiol. 2014 Dec;103(6 Suppl 3):1-86.","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"key20210719142633_B87","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jcct.2019.06.008","article-title":"Long-term health outcomes and cost-effectiveness of coronary CT angiography in patients with suspicion for acute coronary syndrome","volume":"14","author":"Goehler","year":"2020","unstructured":"87. Goehler A, Mayrhofer T, Pursnani A, Ferencik M, Lumish HS, Barth C, et al. Long-term health outcomes and cost-effectiveness of coronary CT angiography in patients with suspicion for acute coronary syndrome. J Cardiovasc Comput Tomogr. 2020 Jan-Feb;14(1):44-54.","journal-title":"J Cardiovasc Comput Tomogr"},{"issue":"7578","key":"key20210719142633_B88","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/bmj.38985.646481.55","article-title":"Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)","volume":"333","author":"Fox","year":"2006","unstructured":"88. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van der Wef F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091.","journal-title":"BMJ"},{"issue":"19","key":"key20210719142633_B89","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/archinte.163.19.2345","article-title":"Predictors of hospital mortality in the Global Registryof Acute Coronary Events","volume":"163","author":"Granger","year":"2003","unstructured":"89. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the Global Registryof Acute Coronary Events. Arch Intern Med. 2003;163(19):2345-53.","journal-title":"Arch Intern Med"},{"issue":"2","key":"key20210719142633_B90","doi-asserted-by":"crossref","first-page":"e004425","DOI":"10.1136\/bmjopen-2013-004425","article-title":"Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score","volume":"4","author":"Fox","year":"2014","unstructured":"90. Fox KAA, FitzGerald G, Puymirat E,Huang W, Carruthers K, Simon T, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4(2):e004425.","journal-title":"BMJ Open"},{"issue":"3","key":"key20210719142633_B91","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(00)00889-5","article-title":"ACC\/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)","volume":"36","author":"Braunwald","year":"2000","unstructured":"91. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC\/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000 Sep;36(3):970-1062.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"key20210719142633_B92","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding Score","volume":"119","author":"Subherwal","year":"2009","unstructured":"92. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK,et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding Score. Circulation. 2009;119(14):1873\u201382.","journal-title":"Circulation"},{"issue":"6","key":"key20210719142633_B93","first-page":"511","article-title":"The bleeding risk score as a mortality predictor in patients with acute coronary syndrome","volume":"101","author":"Nicolau","year":"2013","unstructured":"93. Nicolau JC, Moreira HG, Baracioli LM, Serrano CV Jr, Lima FG, Franken M, et al. The bleeding risk score as a mortality predictor in patients with acute coronary syndrome. Arq Bras Cardiol. 2013 Dec;101(6):511-8.","journal-title":"Arq Bras Cardiol"},{"issue":"23","key":"key20210719142633_B94","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","unstructured":"94. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ,et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55(23):2556\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"key20210719142633_B95","first-page":"ehaa575","article-title":"ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","author":"Collet","year":"2020","unstructured":"95. Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020 Aug 29:ehaa575.","journal-title":"Eur Heart J"},{"issue":"6","key":"key20210719142633_B96","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF03086144","article-title":"Chest pain in the emergency room: value of the Heart score","volume":"16","author":"Six","year":"2008","unstructured":"96. Six AJ, Backaus BE, Kelder SC, Chest pain in the emergency room: value of the Heart score. Neth Heart J.2008;16(6):191-6.","journal-title":"Neth Heart J"},{"issue":"23","key":"key20210719142633_B97","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jacc.2012.02.035","article-title":"2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial","volume":"59","author":"Than","year":"2012","unstructured":"97. Than M, Cullen L, Aldous S, Goodacre S, Frampton CM, Troughton R, et al. 2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. J Am Coll Cardiol. 2012;59(23):2091-8.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20210719142633_B98","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/1742-6723.12164","article-title":"Development and validation of the Emergency Department Assessment of Chest pain Score and 2 h accelerated diagnostic protocol","volume":"26","author":"Than","year":"2014","unstructured":"98. Than M,Flaws D, Sanders S, Doust J, Glasziou P, Kline J, et al. Development and validation of the Emergency Department Assessment of Chest pain Score and 2 h accelerated diagnostic protocol. Emerg Med Australas.2014;26(1):34-44.","journal-title":"Emerg Med Australas"},{"issue":"4","key":"key20210719142633_B99","doi-asserted-by":"crossref","first-page":"439.e3","DOI":"10.1016\/j.annemergmed.2017.10.030","article-title":"Diagnostic Accuracy of a New High-Sensitivity Troponin I Assay and Five Accelerated Diagnostic Pathways for Ruling Out Acute Myocardial Infarction and Acute Coronary Syndrome","volume":"71","author":"Greenslade","year":"2018","unstructured":"99. Greenslade JH et al. Diagnostic Accuracy of a New High-Sensitivity Troponin I Assay and Five Accelerated Diagnostic Pathways for Ruling Out Acute Myocardial Infarction and Acute Coronary Syndrome. Ann Emerg Med. 2018;71(4):439-51.e3.","journal-title":"Ann Emerg Med"},{"issue":"3","key":"key20210719142633_B100","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11739-016-1461-3","article-title":"The HEART score with high-sensitive troponin T at presentation: ruling out patients with chest pain in the emergency room","volume":"12","author":"Santi","year":"2017","unstructured":"100. Santi L, Farina G, Gramenzi A, Trevisani F, Baccini M, Bernardi M, et al. The HEART score with high-sensitive troponin T at presentation: ruling out patients with chest pain in the emergency room. Intern Emerg Med. 2017;12(3):357-64.","journal-title":"Intern Emerg Med"},{"issue":"13","key":"key20210719142633_B101","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/heartjnl-2014-307288","article-title":"A novel diagnostic protocol to identify patients suitable for discharge after a single high-sensitivity troponin","volume":"101","author":"Carlton","year":"2015","unstructured":"101. Carlton EW, Cullen L, Than M, Gamble J, Khattab A, Greaves K. A novel diagnostic protocol to identify patients suitable for discharge after a single high-sensitivity troponin. Heart. 2015;101(13):1041-6.","journal-title":"Heart"},{"issue":"2","key":"key20210719142633_B102","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034403","article-title":"Acute rule-out of non-ST-segment elevation acute coronary syndrome in the (pre) hospital setting by HEART score assessment and a single point-of-care troponin: rationale and design of the ARTICA randomised trial","volume":"10","author":"Aarts","year":"2020","unstructured":"102. Aarts GWA, Camaro C, van Geuns RJ, et al. Acute rule-out of non-ST-segment elevation acute coronary syndrome in the (pre) hospital setting by HEART score assessment and a single point-of-care troponin: rationale and design of the ARTICA randomised trial. BMJ Open. 2020;10(2): e034403.","journal-title":"BMJ Open"},{"issue":"3","key":"key20210719142633_B103","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/HPC.0b013e3181ec36d8","article-title":"Chest pain in the emergency room: a multicenter validation of the HEART Score","volume":"9","author":"Backus","year":"2010","unstructured":"103. Backus BE, Six AJ, Kelder JC, Mast TP, van den Akker F, Mast EG, Monnink SH, van Tooren RM, Doevendans PA. Chest pain in the emergency room: a multicenter validation of the HEART Score. Crit Pathw Cardiol. 2010 Sep;9(3):164-9.","journal-title":"Crit Pathw Cardiol"},{"key":"key20210719142633_B104","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.ijcard.2013.01.255","article-title":"A prospective validation of the Heart score for chest pain patients at the emergency departament","volume":"168","author":"Backus","year":"2013","unstructured":"104. Backus BE, Six AL, Kelder SC,Bosschaert EG, Mast A, Mosterd RF, et al. A prospective validation of the Heart score for chest pain patients at the emergency departament. Int J Cardiol. 2013; 168:2153-8.","journal-title":"Int J Cardiol"},{"issue":"3","key":"key20210719142633_B105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HPC.0b013e31828b327e","article-title":"The HEART score for the assessment of patients with chest pain in the emergency department: a multinational validation study","volume":"12","author":"Six","year":"2013","unstructured":"105. Six Aj, Cullen L,Backus BE, Greenslade J, Parsonage W, Aldous S, et al. The HEART score for the assessment of patients with chest pain in the emergency department: a multinational validation study. Crit Pahtw Cardiol. 2013;12(3):121-6.","journal-title":"Crit Pahtw Cardiol"},{"issue":"2","key":"key20210719142633_B106","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2048872617710788","article-title":"The HEART score for early rule out of acute coronary syndromes in the emergency department: a systematic review and meta-analysis","volume":"7","author":"Van Den Berg","year":"2018","unstructured":"106. Van Den Berg P, Body R. The HEART score for early rule out of acute coronary syndromes in the emergency department: a systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care. 2018; 7(2): 111\u20139.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"key20210719142633_B107","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijcard.2016.10.080","article-title":"Comparison of the GRACE, HEART and TIMI score to predict major adverse cardiac events in chest pain patients at the emergency department","volume":"227","author":"Poldervaart","year":"2017","unstructured":"107. Poldervaart JM, Langedijk M, Backus BE, Dekker IMC, Six AJ, Doevendans PA, Hoes AW, Reitsma JB. Comparison of the GRACE, HEART and TIMI score to predict major adverse cardiac events in chest pain patients at the emergency department. Int J Cardiol. 2017 Jan 15;227:656-61.","journal-title":"Int J Cardiol"},{"key":"key20210719142633_B108","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijcard.2016.07.147","article-title":"Comparing HEART, TIMI, and GRACE scores for prediction of 30-day major adverse cardiac events in high acuity chest pain patients in the emergency department","volume":"221","author":"Sakamoto","year":"2016","unstructured":"108. Sakamoto JT, Liu N, Koh ZX, Fung NX, Heldeweg ML, Ng JC. Comparing HEART, TIMI, and GRACE scores for prediction of 30-day major adverse cardiac events in high acuity chest pain patients in the emergency department. Int J Cardiol. 2016 Oct 15;221:759-64.","journal-title":"Int J Cardiol"},{"issue":"2","key":"key20210719142633_B109","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCOUTCOMES.114.001384","article-title":"The HEART Pathway randomized trial: identifying emergency department patients with acute chest pain for early discharge","volume":"8","author":"Mahler","year":"2015","unstructured":"109. Mahler SA, Riley RF, Hiestand BC, Russell GB, Hoekstra JW, Lefebvre CW, et al. The HEART Pathway randomized trial: identifying emergency department patients with acute chest pain for early discharge. Circ Cardiovasc Qual Outcomes. 2015;8(2):195-203.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"key20210719142633_B110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/acem.13504","article-title":"The HEART Pathway Randomized Controlled Trial One-year Outcomes","volume":"26","author":"Stopyra","year":"2019","unstructured":"110. Stopyra JP, Riley RF, Hiestand BC, Russell G, Holkstra JW, Lefebvre CW, et al. The HEART Pathway Randomized Controlled Trial One-year Outcomes. Acad Emerg Med. 2019;26(1):41-50.","journal-title":"Acad Emerg Med"},{"issue":"2","key":"key20210719142633_B111","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/jamainternmed.2017.7360","article-title":"Noninvasive Cardiac Testing vs Clinical Evaluation Alone in Acute Chest Pain: A Secondary Analysis of the ROMICAT-II Randomized Clinical Trial","volume":"178","author":"Reinhardt","year":"2018","unstructured":"111. Reinhardt SW, Lin CJ, Novak E, Brown DL. Noninvasive Cardiac Testing vs Clinical Evaluation Alone in Acute Chest Pain: A Secondary Analysis of the ROMICAT-II Randomized Clinical Trial. JAMA Intern Med. 2018;178(2):212-9.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"key20210719142633_B112","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1474515113488026","article-title":"Nurse-led Early Triage (NET) study of chest pain patients: a long term evaluation study of a service development aimed at improving the management of patients with non-ST-elevation acute coronary syndromes","volume":"13","author":"O\u2019Neill","year":"2014","unstructured":"112. O\u2019Neill L, Smith K, Currie P,Elder Dhj, Wei J, Lang CC. et al. Nurse-led Early Triage (NET) study of chest pain patients: a long term evaluation study of a service development aimed at improving the management of patients with non-ST-elevation acute coronary syndromes. Eur J Cardiovasc Nurs. 2014; 13(3):253\u201360.","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"1","key":"key20210719142633_B113","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s12913-017-2395-9","article-title":"The effectiveness of emergency nurse practitioner service in the management of patients presenting to rural hospitals with chest pain: a multisite prospective longitudinal nested cohort study","volume":"17","author":"Roche","year":"2017","unstructured":"113. Roche TE, Gardner G, Jack L. The effectiveness of emergency nurse practitioner service in the management of patients presenting to rural hospitals with chest pain: a multisite prospective longitudinal nested cohort study. BMC Health Serv Res. 2017; 17(1): 445.","journal-title":"BMC Health Serv Res"},{"issue":"24","key":"key20210719142633_B114","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1161\/CIRCULATIONAHA.114.014494","article-title":"Air versus oxygen in ST-segment-elevation myocardial infarction","volume":"131","author":"Stub","year":"2015","unstructured":"114. Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, eet al. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation 2015;131(24):2143\u201450.","journal-title":"Circulation"},{"issue":"13","key":"key20210719142633_B115","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1706222","article-title":"Oxygen Therapy in Suspected Acute Myocardial Infarction","volume":"377","author":"Hofmann","year":"2017","unstructured":"115. Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N,et al. Oxygen Therapy in Suspected Acute Myocardial Infarction. N Engl J Med. 2017 Sep 28;377(13):1240-9.","journal-title":"N Engl J Med"},{"issue":"7","key":"key20210719142633_B116","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jacc.2013.10.068","article-title":"Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Hobl","year":"2014","unstructured":"116. Hobl EL, Stimpfl T, Ebner J, Schoergenjofer C, Derhaschnig U, Plassman RS, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014;63(7):630\u20135.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"key20210719142633_B117","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1160\/TH16-02-0102","article-title":"Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction","volume":"116","author":"Thomas","year":"2016","unstructured":"117. Thomas MR, Morton AC, Hossain R, Chen b, Luo L, Shahari NN, et al. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost. 2016; 116(7):96\u2013102.","journal-title":"Thromb Haemost"},{"issue":"3","key":"key20210719142633_B118","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","author":"Kubica","year":"2016","unstructured":"118. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Srooka WD, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37(3):245-52.","journal-title":"Eur Heart J"},{"issue":"6","key":"key20210719142633_B119","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ahj.2005.02.010","article-title":"CRUSADE Investigators. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative","volume":"149","author":"Meine","year":"2005","unstructured":"119. Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, Ohman EM, et al; CRUSADE Investigators. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005;149(6):1043-9.","journal-title":"Am Heart J"},{"issue":"3","key":"key20210719142633_B120","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025232","article-title":"Morphine in acute coronary syndrome: systematic review and meta-analysis","volume":"9","author":"Duarte","year":"2019","unstructured":"120. Duarte GS, Nunes-Ferreira A, Rodrigues FB, Pinto FJ, Ferreira JJ, Costa J, et al. Morphine in acute coronary syndrome: systematic review and meta-analysis. BMJ Open. 2019;9(3):e025232.","journal-title":"BMJ Open"},{"issue":"3","key":"key20210719142633_B121","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jacc.2019.11.035","article-title":"Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography","volume":"75","author":"Furtado","year":"2020","unstructured":"121. Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, et al Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. J Am Coll Cardiol. 2020 Jan 28;75(3):289-300.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"key20210719142633_B122","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/hrt.43.5.535","article-title":"Diazepam in immediate post-myocardial infarct period. A double blind trial","volume":"43","author":"Dixon","year":"1980","unstructured":"122. Dixon RA, Edwards IR, Pilcher J. Diazepam in immediate post-myocardial infarct period. A double blind trial. Br Heart J.1980 May;43(5):535-40.","journal-title":"Br Heart J"},{"issue":"25","key":"key20210719142633_B123","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1161\/CIRCULATIONAHA.106.616219","article-title":"Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction","volume":"113","author":"Gislason","year":"2006","unstructured":"123. Gislason GH, Jacobsen S, Rasmussen JN,Rasmussen S, Bucch P, Fribens J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906\u201313.","journal-title":"Circulation"},{"issue":"3","key":"key20210719142633_B124","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.amjcard.2005.03.076","article-title":"Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome","volume":"96","author":"Conaway","year":"2005","unstructured":"124. Conaway DG, O\u2019Keefe JH, Reid KJ, Spertus J. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol. 2005;96(3):363\u20135.","journal-title":"Am J Cardiol"},{"issue":"11","key":"key20210719142633_B125","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehi884","article-title":"Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study","volume":"27","author":"Goyal","year":"2006","unstructured":"125. Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD, Theroux P, Oliveira GB, Todaro TG, Mojcik CF, Armstrong PW, Granger CB. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J. 2006 Jun;27(11):1289-97.","journal-title":"Eur Heart J"},{"issue":"1","key":"key20210719142633_B126","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/dc11-1170","article-title":"In patients with acute myocardial infarction, the impact of hyperglycemia as a risk factor for mortality is not homogeneous across age-groups","volume":"35","author":"Nicolau","year":"2012","unstructured":"126. Nicolau JC, Serrano CV Jr, Giraldez RR, Baracioli LM, Moreira HG, Lima F, et al. In patients with acute myocardial infarction, the impact of hyperglycemia as a risk factor for mortality is not homogeneous across age-groups. Diabetes Care. 2012 Jan;35(1):150-2.","journal-title":"Diabetes Care"},{"issue":"13","key":"key20210719142633_B127","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJMoa0810625","article-title":"Intensive versus conventional glucose control in critically ill patients","volume":"360","author":"Finfer","year":"2009","unstructured":"127. Finfer S, Chittock DR, Su SY, Bleir D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283\u201397.","journal-title":"N Engl J Med"},{"issue":"10","key":"key20210719142633_B128","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1001\/archinte.1982.00340230046009","article-title":"Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action","volume":"142","author":"DePace","year":"1982","unstructured":"128. DePace NL, Herling IM, Kotler MN, Hakki AH, Spielman SR, Segal BL. Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action. Arch Intern Med. 1982 Oct;142(10):1806-9.","journal-title":"Arch Intern Med"},{"issue":"5","key":"key20210719142633_B129","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0002-9149(83)80117-9","article-title":"Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy","volume":"51","author":"Kaplan","year":"1983","unstructured":"129. Kaplan K, Davison R, Parker M, Przybylek J, Teagarden JR, Lesch M. Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy. Am J Cardiol.1983 Mar 1;51(5):694-8.","journal-title":"Am J Cardiol"},{"issue":"6","key":"key20210719142633_B130","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1445-5994.1982.tb02645.x","article-title":"Intravenous nitroglycerine in refractory unstable angina pectoris","volume":"12","author":"Roubin","year":"1982","unstructured":"130. Roubin GS, Harris PJ, Eckhardt I, Hensley W, Kelly DT. Intravenous nitroglycerine in refractory unstable angina pectoris. Aust N Z J Med. 1982 Dec;12(6):598-602.","journal-title":"Aust N Z J Med"},{"issue":"2","key":"key20210719142633_B131","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.CIR.67.2.276","article-title":"Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective, randomized trial","volume":"67","author":"Curfman","year":"1983","unstructured":"131. Curfman GD, Heinsimer JA, Lozner EC, Fung HL. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective, randomized trial. Circulation. 1983 Feb;67(2):276-82.","journal-title":"Circulation"},{"issue":"1","key":"key20210719142633_B132","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00280098","article-title":"Buccal versus intravenous nitroglycerin in unstable angina pectoris","volume":"41","author":"Dellborg","year":"1991","unstructured":"132. Dellborg M, Gustafsson G, Swedberg K. Buccal versus intravenous nitroglycerin in unstable angina pectoris. Eur J Clin Pharmacol. 1991;41(1):5-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"key20210719142633_B133","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/01.CIR.73.2.331","article-title":"Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomized, double-blind, placebo-controlled trial","volume":"73","author":"Gottlieb","year":"1986","unstructured":"133. Gottlieb SO, Weisfeldt ML, Ouyang P, Achuff SC, Baughman KL, Traill TA, et al. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomized, double-blind, placebo-controlled trial. Circulation. 1986 Feb;73(2):331-7.","journal-title":"Circulation"},{"issue":"8232","key":"key20210719142633_B134","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(81)92399-0","article-title":"Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome","volume":"1","author":"Telford","year":"1981","unstructured":"134. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet. 1981 Jun 6;1(8232):1225-8.","journal-title":"Lancet"},{"issue":"2","key":"key20210719142633_B135","doi-asserted-by":"crossref","first-page":"18A","DOI":"10.1016\/0002-9149(87)90494-2","article-title":"Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine\/metoprolol Trial (HINT)","volume":"60","author":"Lubsen","year":"1987","unstructured":"135. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine\/metoprolol Trial (HINT). Am J Cardiol. 1987 Jul 15;60(2):18A-25A.","journal-title":"Am J Cardiol"},{"issue":"15","key":"key20210719142633_B136","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1001\/jama.1988.03410150107041","article-title":"Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification","volume":"260","author":"Yusuf","year":"1988","unstructured":"136. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA. 1988 Oct 21;260(15):2259-63.","journal-title":"JAMA"},{"issue":"5","key":"key20210719142633_B137","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10557-018-6818-6","article-title":"The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study","volume":"32","author":"Nicolau","year":"2018","unstructured":"137. Nicolau JC, Furtado RHM, Baracioli LM, Lara LM, Dal\u00e7\u00f3quio TF, Scanavini Junior MA, et al. The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study. Cardiovasc Drugs Ther. 2018 Oct;32(5):435-42.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"9497","key":"key20210719142633_B138","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(05)67661-1","article-title":"Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","unstructured":"138. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 Nov 5;366(9497):1622-32.","journal-title":"Lancet"},{"issue":"5","key":"key20210719142633_B139","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ahj.2011.01.006","article-title":"Treatment and outcomes in patients with myocardial infarction treated with acute \u03b2-blocker therapy: results from the American College of Cardiology's NCDR(\u00ae)","volume":"161","author":"Kontos","year":"2011","unstructured":"139. Kontos MC, Diercks DB, Ho PM, Wang TY, Chen AY, Roe MT. Treatment and outcomes in patients with myocardial infarction treated with acute \u03b2-blocker therapy: results from the American College of Cardiology's NCDR(\u00ae). Am Heart J. 2011 May;161(5):864-70.","journal-title":"Am Heart J"},{"issue":"12","key":"key20210719142633_B140","doi-asserted-by":"crossref","first-page":"115566","DOI":"10.1161\/CIRCULATIONAHA.117.029870","article-title":"Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment","volume":"136","author":"Crea","year":"2017","unstructured":"140. Crea F, Libby P. Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment. Circulation. 2017 Sep 19;136(12):115566.","journal-title":"Circulation"},{"issue":"12","key":"key20210719142633_B141","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1161\/CIRCRESAHA.114.302737","article-title":"Antiplatelet and anticoagulation therapy for acute coronary syndromes","volume":"114","author":"Bhatt","year":"2014","unstructured":"141. Bhatt DL, Hulot JS, Moliterno DJ, Harrington RA. Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res. 2014;114(12):1929-43.","journal-title":"Circ Res"},{"issue":"8","key":"key20210719142633_B142","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1161\/CIRCULATIONAHA.106.675934","article-title":"Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications","volume":"115","author":"L\u00fcscher","year":"2007","unstructured":"142. L\u00fcscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007 Feb 27;115(8):1051-8.","journal-title":"Circulation"},{"key":"key20210719142633_B143","doi-asserted-by":"crossref","first-page":"g6269","DOI":"10.1136\/bmj.g6269","article-title":"Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis","volume":"349","author":"Bellemain-Appaix","year":"2014","unstructured":"143. Bellemain-Appaix A, Kerneis M, O\u2019Connor SA, Silvain J, Cucherat M, Beygui F, et al. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ.2014;349:g6269.","journal-title":"BMJ"},{"issue":"4-5","key":"key20210719142633_B144","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.pcad.2018.01.001","article-title":"The Timing of P2Y Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?","volume":"60","author":"Golwala","year":"2018","unstructured":"144. Golwala H, Bhatt DL. The Timing of P2Y12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era? Prog Cardiovasc Dis. 2018 Jan-Feb;60(4-5):471-7.","journal-title":"Prog Cardiovasc Dis"},{"issue":"10","key":"key20210719142633_B145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.18735","article-title":"Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non\u2013ST-Segment Elevation Acute Coronary Syndromes With Outcomes","volume":"3","author":"Dworeck","year":"2020","unstructured":"145. Dworeck C, Redfors B, Anger\u00e5s O, Haraldsson I, Odenstedt J, Ioanes D, et al. Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non\u2013ST-Segment Elevation Acute Coronary Syndromes With Outcomes. JAMA Netw Open. 2020;3(10):e2018735.","journal-title":"JAMA Netw Open"},{"issue":"25","key":"key20210719142633_B146","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","article-title":"PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial","volume":"116","author":"Wiviott","year":"2007","unstructured":"146. Wiviott SD, Trenk D, Frelinger AL, O\u2019Donoghue M, Neumann FJ, Michelson AD, et al. PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18;116(25):2923-32.","journal-title":"Circulation"},{"issue":"25","key":"key20210719142633_B147","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","unstructured":"147. Gurbel PA1, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation. 2009 Dec 22;120(25):2577-85.","journal-title":"Circulation"},{"issue":"4","key":"key20210719142633_B148","first-page":"702","article-title":"Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome","volume":"114","author":"Bonello","year":"2015","unstructured":"148. Bonello L, Laine M, Camoin-Jau L, Noirot F, Guieu R, Dignet-George F, et al. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. Thromb Haemost. 2015;114(4):702-7.","journal-title":"Thromb Haemost"},{"issue":"1","key":"key20210719142633_B149","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/MJT.0000000000000350","article-title":"Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis","volume":"23","author":"Singh","year":"2016","unstructured":"149. Singh S, Singh M, Grewal N, Khosla S. Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis. Am J Ther. 2016;23(1):e52-e62.","journal-title":"Am J Ther"},{"issue":"7","key":"key20210719142633_B150","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation: the clopidogrel in unstable angina to prevent recurrent events trial investigators","volume":"345","author":"Yusuf","year":"2001","unstructured":"150. Yusuf S, Bijsterveld N, Moons A. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation: the clopidogrel in unstable angina to prevent recurrent events trial investigators. New Engl J Med. 2001; 345(7):494\u2013502.","journal-title":"New Engl J Med"},{"issue":"9281","key":"key20210719142633_B151","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","unstructured":"151. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-33.","journal-title":"Lancet"},{"issue":"1","key":"key20210719142633_B152","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","unstructured":"152. Wallentin L, Becker RC, Budaj A, Cannon CP, Emmanuelson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(1):1045-57.","journal-title":"N Engl J Med"},{"issue":"9791","key":"key20210719142633_B153","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"PLATelet inhibition and patient Outcomes (PLATO) investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"375","author":"Cannon","year":"2010","unstructured":"153. Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H et al. PLATelet inhibition and patient Outcomes (PLATO) investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010; 375(9791): 283\u201393.","journal-title":"Lancet"},{"issue":"20","key":"key20210719142633_B154","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","unstructured":"154. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20): 2001-15.","journal-title":"N Engl J Med"},{"issue":"7","key":"key20210719142633_B155","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2010.01.067","article-title":"Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention","volume":"56","author":"Di Sciascio","year":"2010","unstructured":"155. Di Sciascio MG, Patti G, Pasceri V, Gatto L. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol.2010;56(7):550-7.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"key20210719142633_B156","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","unstructured":"156. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, Delago A, Wilmer CH, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411-20.","journal-title":"JAMA"},{"issue":"11","key":"key20210719142633_B157","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non\u2013ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","unstructured":"157. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay J-F, ten Berg JM, et al. Pretreatment with prasugrel in non\u2013ST-segment elevation acute coronary syndromes. N Engl J Med. 369(11):999\u20131010.","journal-title":"N Engl J Med"},{"key":"key20210719142633_B158","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2020.08.053","article-title":"Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome","author":"Tarantini","year":"2020","unstructured":"158. Tarantini G, Mojoli M, Varbella F,Caporale R, Riggatieri S, Condo G, et al. Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome. J Am Coll Cardiol. 2020;S0735-1097(20)36444-5.","journal-title":"J Am Coll Cardiol"},{"key":"key20210719142633_B159","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2016.11.226","article-title":"Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy","volume":"229","author":"Nairooz","year":"2017","unstructured":"159. Nairooz R, Valgimigli M, Rochlani Y, Pothineni NV, Raina S, Sardar P, et al. Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. Int J Cardiol. 2017 Feb 15;229:82-9.","journal-title":"Int J Cardiol"},{"issue":"6","key":"key20210719142633_B160","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1055\/s-0039-1683421","article-title":"Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis","volume":"119","author":"Komosa","year":"2019","unstructured":"160. Komosa A, Lesiak M, Krasi\u0144ski Z, Grygier M, Siniawski A, Skorupski W, et al. Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis. Thromb Haemost. 2019 Jun;119(6):1000-20.","journal-title":"Thromb Haemost"},{"issue":"25","key":"key20210719142633_B161","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"the TARGET Investigators. Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","unstructured":"161. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. the TARGET Investigators. Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344(25):1888\u201394.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20210719142633_B162","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/eurheartj\/ehp376","article-title":"Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials","volume":"31","author":"Valgimigli","year":"2010","unstructured":"162. Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AWJ, Campo G, Hamm C, et al.T irofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010;31(1):35-49.","journal-title":"Eur Heart J"},{"issue":"25","key":"key20210719142633_B163","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban","volume":"344","author":"Cannon","year":"2001","unstructured":"163. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban. N Engl J Med 2001 Jun 21;344(25):1879-87.","journal-title":"N Engl J Med"},{"issue":"9247","key":"key20210719142633_B164","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial","volume":"356","year":"2000","unstructured":"164. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000 Dec 16;356(9247):2037-44.","journal-title":"Lancet"},{"issue":"21","key":"key20210719142633_B165","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina","volume":"338","year":"1998","unstructured":"165. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998 May 21;338(21):1498-505.","journal-title":"N Engl J Med"},{"issue":"24","key":"key20210719142633_B166","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.CIR.97.24.2386","article-title":"International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb\/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb\/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network","volume":"97","year":"1998","unstructured":"166. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb\/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb\/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation. 1998 Jun 23;97(24):2386-95.","journal-title":"Circulation"},{"issue":"7","key":"key20210719142633_B167","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","year":"1998","unstructured":"167. Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998 Aug 13;339(7):436-43.","journal-title":"N Engl J Med"},{"issue":"6","key":"key20210719142633_B168","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1067\/mhj.2002.126118","article-title":"Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb\/IIIa inhibition: results from Platelet IIb\/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)","volume":"144","author":"Mukherjee","year":"2002","unstructured":"168. Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, et al. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb\/IIIa inhibition: results from Platelet IIb\/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J. 2002 Dec;144(6):995-1002.","journal-title":"Am Heart J"},{"issue":"9272","key":"key20210719142633_B169","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial","volume":"357","author":"Simoons","year":"2001","unstructured":"169. Simoons ML. Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001 Jun 16;357(9272):1915-24.","journal-title":"Lancet"},{"issue":"9302","key":"key20210719142633_B170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","unstructured":"170. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de WF, et al. Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002 Jan 19;359(9302):189-98.","journal-title":"Lancet"},{"issue":"14","key":"key20210719142633_B171","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","year":"1994","unstructured":"171. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994 Apr 7;330(14):956-61.","journal-title":"N Engl J Med"},{"issue":"9063","key":"key20210719142633_B172","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study","volume":"349","year":"1997","unstructured":"172. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997 May 17;349(9063):1429-35. Erratum in: Lancet 1997 Sep 6;350(9079):744.","journal-title":"Lancet"},{"issue":"24","key":"key20210719142633_B173","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators","volume":"336","year":"1997","unstructured":"173. Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med. 1997 Jun 12;336(24):1689-96.","journal-title":"N Engl J Med"},{"issue":"9122","key":"key20210719142633_B174","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)85010-1","article-title":"EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","year":"1998","unstructured":"174. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade. Lancet. 1998 Jul 11;352(9122):87-92.","journal-title":"Lancet"},{"issue":"9063","key":"key20210719142633_B175","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II","volume":"349","year":"1997","unstructured":"175. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997 May 17;349(9063):1422-8.","journal-title":"Lancet"},{"issue":"5","key":"key20210719142633_B176","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis","volume":"96","year":"1997","unstructured":"176. Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation. 1997 Sep 2;96(5):1445-53.","journal-title":"Circulation"},{"issue":"19","key":"key20210719142633_B177","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1001\/jama.285.19.2468","article-title":"Platelet glycoprotein IIb\/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial","volume":"285","author":"O'shea","year":"2001","unstructured":"177. O'shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al. Platelet glycoprotein IIb\/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA. 2001 May 16;285(19):2468-73.","journal-title":"JAMA"},{"issue":"1","key":"key20210719142633_B178","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0735-1097(02)02666-9","article-title":"Intravenous glycoprotein IIb\/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions","volume":"41","author":"Karvouni","year":"2003","unstructured":"178. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb\/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003 Jan 1;41(1):26-32.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"key20210719142633_B179","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial","volume":"295","author":"Kastrati","year":"2006","unstructured":"179. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, Ten BJ, Bollwein H, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006 Apr 5;295(13):1531-8.","journal-title":"JAMA"},{"issue":"6","key":"key20210719142633_B180","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.297.6.591","article-title":"Routine upstream initiation vs deferred selective use of glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial","volume":"297","author":"Stone","year":"2007","unstructured":"180. Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007 Feb 14;297(6):591-602.","journal-title":"JAMA"},{"issue":"21","key":"key20210719142633_B181","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","unstructured":"181. Giugliano RP, White JA, Bode C, Armstrong Pw, Montalescot G, Lewis BS, et al. et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360(21):2176 \u201390.","journal-title":"N Engl J Med"},{"issue":"9219","key":"key20210719142633_B182","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis","volume":"355","author":"Eikelboom","year":"2000","unstructured":"182. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000 Jun 3;355(9219):1936-42.","journal-title":"Lancet"},{"issue":"1","key":"key20210719142633_B183","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijcard.2009.03.119","article-title":"Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY","volume":"144","author":"Spinler","year":"2010","unstructured":"183. Spinler SA, Mahaffey KW, Gallup D, Levine GM, Ferguson JJ, Rao SV,et al. Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol. 2010;144(1):36-41.","journal-title":"Int J Cardiol"},{"issue":"1","key":"key20210719142633_B184","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2004.10.004","article-title":"Dosage of enoxaparin among obese and renal impairment patients","volume":"116","author":"Bazinet","year":"2005","unstructured":"184. Bazinet A, Almanric K, Brunet C,Martineau J, Turcotte I, Caron S, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005;116(1):41-50.","journal-title":"Thromb Res"},{"key":"key20210719142633_B185","first-page":"e24S","volume-title":"Chest","author":"Garcia","year":"2012","unstructured":"185. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 May;141(2 Suppl):e24S-e43S.","edition":"9th ed"},{"issue":"4","key":"key20210719142633_B186","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s11239-014-1117-y","article-title":"Assessing an enoxaparin dosing protocol in morbidly obese patients","volume":"39","author":"Lalama","year":"2015","unstructured":"186. Lalama JT, Feeney ME, Vandiver JW, Beavers KD, Walter LN, McClintic JR. Assessing an enoxaparin dosing protocol in morbidly obese patients. J Thromb Thrombolysis. 2015;39(4):516-21.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"key20210719142633_B187","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40261-019-00855-9","article-title":"Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study","volume":"40","author":"Lee","year":"2020","unstructured":"187. Lee YR, Palmere PJ, Burton CE, Benavides TM. Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study. Clin Drug Investig. 2020;40(1):33-40.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"key20210719142633_B188","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1592\/phco.29.6.631","article-title":"Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative","volume":"29","author":"Spinler","year":"2009","unstructured":"188. Spinler SA, Ou FS, Roe MT, Gibler WB, Ohman EM, Pollack CV,et al. Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. Pharmacotherapy. 2009 Jun;29(6):631-8.","journal-title":"Pharmacotherapy"},{"key":"key20210719142633_B189","first-page":"002","article-title":"Enoxaparin Dosing for Acute Coronary Syndromes in Obese Patients-Should There be a Maximum Dose","volume":"1","author":"Chua","year":"2016","unstructured":"189. Chua D, Tataru A. Enoxaparin Dosing for Acute Coronary Syndromes in Obese Patients-Should There be a Maximum Dose. J Cardio Cardiovasc Med. 2016;1:002.","journal-title":"J Cardio Cardiovasc Med"},{"issue":"6","key":"key20210719142633_B190","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ahj.2006.08.002","article-title":"Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb\/IIIa Inhibitors (SYNERGY) trial [published correction appears in Am Heart J","volume":"152","author":"White","year":"2006","unstructured":"190. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper K, Cheswell K. et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb\/IIIa Inhibitors (SYNERGY) trial [published correction appears in Am Heart J. 2007 Feb;153(2):327]. Am Heart J. 2006;152(6):1042-50.","journal-title":"Am Heart J"},{"key":"key20210719142633_B191","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e553","article-title":"Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis","volume":"344","author":"Silvain","year":"2012","unstructured":"191. Silvain J, Beygui F, Barthelemy O, Pollack C, Jr., Cohen M, Zeymer U, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344:e553.","journal-title":"BMJ"},{"issue":"1","key":"key20210719142633_B192","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jama.292.1.89","article-title":"Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview","volume":"292","author":"Petersen","year":"2004","unstructured":"192. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004; 292(1): 89\u201396.","journal-title":"JAMA"},{"issue":"4 Suppl","key":"key20210719142633_B193","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.ahj.2005.02.021","article-title":"A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes","volume":"149","author":"Califf","year":"2005","unstructured":"193. Califf RM, Petersen JL, Hasselblad V, Mahaffey KW, Ferguson JJ. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. Am Heart J. 2005 Apr;149(4 Suppl):S91-9.","journal-title":"Am Heart J"},{"issue":"14","key":"key20210719142633_B194","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","unstructured":"194. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006 Apr 6;354(14):1464-76.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20210719142633_B195","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1586\/14779072.7.3.241","article-title":"Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6","volume":"7","author":"Karthikeyan","year":"2009","unstructured":"195. Karthikeyan G, Mehta SR, Eikelboom JW. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. Expert Rev Cardiovasc Ther. 2009 Mar;7(3):241-9.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"1","key":"key20210719142633_B196","first-page":"111","article-title":"Posicionamento sobre Antiagregantes Plaquet\u00e1rios e Anticoagulantes em Cardiologia \u2013 2019","volume":"113","author":"Serrano","year":"2019","unstructured":"196. Serrano Jr. CV, Soeiro AM, Leal TCAT, Godoy LC, Biselli B, Hata LA et al. Posicionamento sobre Antiagregantes Plaquet\u00e1rios e Anticoagulantes em Cardiologia \u2013 2019. Arq Bras Cardiol. 2019; 113(1):111-34.","journal-title":"Arq Bras Cardiol"},{"issue":"9","key":"key20210719142633_B197","doi-asserted-by":"crossref","DOI":"10.1161\/HCV.0000000000000035","article-title":"An Update on Radial Artery Access and Best Practices for Transradial Coronary Angiography and Intervention in Acute Coronary Syndrome: A Scientific Statement From the American Heart Association","volume":"11","author":"Mason","year":"2018","unstructured":"197. Mason PJ, Shah B, Tamis-Holland JE,Bitt JA, Cohen MG, Safirstein J, et al. An Update on Radial Artery Access and Best Practices for Transradial Coronary Angiography and Intervention in Acute Coronary Syndrome: A Scientific Statement From the American Heart Association. Circ Cardiovasc Interv. 2018;11(9):e000035. doi:10.1161\/HCV.0000000000000035","journal-title":"Circ Cardiovasc Interv"},{"issue":"25","key":"key20210719142633_B198","first-page":"e344","article-title":"2014 AHA\/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes","volume":"130","author":"Amsterdam","year":"2014","unstructured":"198. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganisats TG, Holmes DR, et al. 2014 AHA\/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes. Circulation. 2014;130(25):e344-e426.","journal-title":"Circulation"},{"issue":"6","key":"key20210719142633_B199","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0002-9149(97)01006-0","article-title":"Effects of Prior Aspirin and Anti-Ischemic Therapy on Outcome of Patients With Unstable Angina","volume":"81","author":"Borzak","year":"1998","unstructured":"199. Borzak S, Cannon C P, Kraft PL, Douthat L, Becker R C, Palmeri S T et al. Effects of Prior Aspirin and Anti-Ischemic Therapy on Outcome of Patients With Unstable Angina. Am J Cardiol.1998;81(6):678-81.","journal-title":"Am J Cardiol"},{"issue":"3","key":"key20210719142633_B200","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0735-1097(85)80400-9","article-title":"A randomized study comparing propranolol and diltiazem in the treatment of unstable angina","volume":"5","author":"Theroux","year":"1985","unstructured":"200. Theroux P, Taeymans Y, Morissette D, Bosch X, Pelletier GB, Waters DD. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol. 1985;5(3):717-22.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"key20210719142633_B201","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0002-9149(86)90727-7","article-title":"Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit","volume":"57","author":"Parodi","year":"1986","unstructured":"201. Parodi O, Simonetti I, Michelassi C, Carpeggiani C, Biagini A, L\u2019Abbate A, et al. Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit. Am J Cardiol. 1986;57(11):899-906.","journal-title":"Am J Cardiol"},{"issue":"6709","key":"key20210719142633_B202","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/bmj.299.6709.1187","article-title":"Calcium channel blockers in acute myocardial infarction and unstable angina: an overview","volume":"299","author":"Held","year":"1989","unstructured":"202. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989;299(6709):1187-92.","journal-title":"BMJ"},{"issue":"5","key":"key20210719142633_B203","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0735-1097(98)00408-2","article-title":"Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina","volume":"32","author":"Smith","year":"1998","unstructured":"203. Smith NL Reiber GE, Psaty BM, Heckbert SR, Siscovick DS, Ritchie JL, et al. Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina. J Am Coll Cardiol. 1998;32(5):1305-11.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"key20210719142633_B204","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/0002-9149(91)90944-G","article-title":"Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies","volume":"67","author":"Yusuf","year":"1991","unstructured":"204. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991;67(15):1295-7.","journal-title":"Am J Cardiol"},{"issue":"9217","key":"key20210719142633_B205","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(00)02262-5","article-title":"Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT)","volume":"355","author":"Boden","year":"2000","unstructured":"205. Boden WE, van Gilst WH, Scheldewaert RG, Starkey IR, Carlier MF, Julian DG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Lancet. 2000;355(9217):1751-6.","journal-title":"Lancet"},{"issue":"2","key":"key20210719142633_B206","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ijcard.2012.01.063","article-title":"Aspirin desensitization in patients under-going planned or urgent coronary stent implantation: a single-center experience","volume":"167","author":"De Luca","year":"2013","unstructured":"206. De Luca G, Verdoia M, Binda G, Schaffer A, Suryapranata H, Marino P. Aspirin desensitization in patients under-going planned or urgent coronary stent implantation: a single-center experience. Int J Cardiol. 2013;167(2):561-3.","journal-title":"Int J Cardiol"},{"issue":"6","key":"key20210719142633_B207","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.amjcard.2007.10.045","article-title":"Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation","volume":"101","author":"Rossini","year":"2008","unstructured":"207. Rossini R, Angiolillo DJ, Musumeci G, Scuri P, Invernizzi P, Bass TA, et al. Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. Am J Cardiol. 2008;101(6):786-9.","journal-title":"Am J Cardiol"},{"issue":"1","key":"key20210719142633_B208","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1345\/aph.1H437","article-title":"Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy","volume":"41","author":"Page","year":"2007","unstructured":"208. Page NA, Schroeder WS. Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy. Ann Pharmacother. 2007;41(1):61-7.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"key20210719142633_B209","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/clc.22054","article-title":"Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease","volume":"36","author":"McMullan","year":"2013","unstructured":"209. McMullan KL, Wedner HJ. Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease. Clin Cardiol. 2013;36(1):25-30.","journal-title":"Clin Cardiol"},{"key":"key20210719142633_B210","first-page":"827","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group","volume-title":"Lancet","year":"1990","unstructured":"210. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet. 1990;336(8719):827-30."},{"issue":"17","key":"key20210719142633_B211","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Theroux","year":"1988","unstructured":"211. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319(17):1105-11.","journal-title":"N Engl J Med"},{"issue":"9748","key":"key20210719142633_B212","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","unstructured":"212. Mehta SR, Tanguay JF, Eikelboom JW, JollySS, J oyner CD, Granger CB, et al; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233-43.","journal-title":"Lancet"},{"issue":"7","key":"key20210719142633_B213","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000051362.96946.15","article-title":"Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes","volume":"107","author":"Yusuf","year":"2003","unstructured":"213. Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, et al; Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003;107(7):966-72.","journal-title":"Circulation"},{"issue":"14","key":"key20210719142633_B214","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"108","author":"Peters","year":"2003","unstructured":"214. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108(14):1682-7.","journal-title":"Circulation"},{"issue":"23","key":"key20210719142633_B215","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","unstructured":"215. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med.1998;339(23):1665-71.","journal-title":"N Engl J Med"},{"issue":"10","key":"key20210719142633_B216","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","unstructured":"216. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, et al; CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930-42. Erratum in: N Engl J Med. 2010;363(16):1585.","journal-title":"N Engl J Med"},{"issue":"8","key":"key20210719142633_B217","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","unstructured":"217. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754-62. Erratum in: JAMA. 2010;303(13):1257. JAMA. 2011;305(21):2174. JAMA. 2011;305(21):2172-3.","journal-title":"JAMA"},{"issue":"24","key":"key20210719142633_B218","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jacc.2007.01.094","article-title":"Impact of platelet reactivity after clopidogrel administration on drugeluting stent thrombosis","volume":"49","author":"Buonamici","year":"2007","unstructured":"218. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drugeluting stent thrombosis. J Am Coll Cardiol. 2007; 49(24): 2312-7.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"key20210719142633_B219","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/eurheartj\/ehn046","article-title":"Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation","volume":"29","author":"Price","year":"2008","unstructured":"219. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, et al. Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29(8):992-1000.","journal-title":"Eur Heart J"},{"issue":"16","key":"key20210719142633_B220","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a metaanalysis","volume":"304","author":"Mega","year":"2010","unstructured":"220. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a metaanalysis. JAMA. 2010;304(16):1821-30.","journal-title":"JAMA"},{"issue":"5","key":"key20210719142633_B221","first-page":"486","article-title":"Impact of P-glycoprotein on clopidogrel absorption","volume":"80","author":"Taubert","year":"2006","unstructured":"221. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin PharmacolTher. 2006;80(5):486-501.","journal-title":"Clin PharmacolTher"},{"issue":"1","key":"key20210719142633_B222","first-page":"65","article-title":"Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies","volume":"89","author":"Angiolillo","year":"2011","unstructured":"222. Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin PharmacolTher. 2011;89(1): 65-74.","journal-title":"Clin PharmacolTher"},{"issue":"13","key":"key20210719142633_B223","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2009.05.050","article-title":"Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study","volume":"54","author":"Cuisset","year":"2009","unstructured":"223. Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009;54(13):1149-53.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"key20210719142633_B224","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.jacc.2011.12.024","article-title":"A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers","volume":"59","author":"Frelinger","year":"2012","unstructured":"224. Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304-11. Erratum in J Am Coll Cardiol. 2012;60(6):566-7.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"key20210719142633_B225","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (OmeprazoleCLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","unstructured":"225. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (OmeprazoleCLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256-60.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"key20210719142633_B226","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","unstructured":"226. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-44.","journal-title":"JAMA"},{"issue":"7","key":"key20210719142633_B227","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pumpinhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","unstructured":"227. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pumpinhibitors and clopidogrel. CMAJ. 2009;180(7):713-8.","journal-title":"CMAJ"},{"issue":"4","key":"key20210719142633_B228","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ahj.2015.05.017","article-title":"TRILOGY ACS investigators. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial","volume":"170","author":"Nicolau","year":"2015","unstructured":"228. Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbal\u00e1n R, et al. TRILOGY ACS investigators. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. Am Heart J. 2015;170(4):683-694.","journal-title":"Am Heart J"},{"issue":"9694","key":"key20210719142633_B229","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: na analysis of two randomised trials","volume":"374","author":"O\u2019Donoghue","year":"2009","unstructured":"229. O\u2019Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: na analysis of two randomised trials. Lancet. 2009;374(9694):989-97.","journal-title":"Lancet"},{"issue":"8","key":"key20210719142633_B230","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","article-title":"Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial","volume":"125","author":"Goodman","year":"2012","unstructured":"230. Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125(8):978-86.","journal-title":"Circulation"},{"issue":"20","key":"key20210719142633_B231","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","unstructured":"231. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-17.","journal-title":"N Engl J Med"},{"issue":"11","key":"key20210719142633_B232","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","unstructured":"232. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-105. Erratum in JAMA. 2011 Jun 1;305(21);2174.","journal-title":"JAMA"},{"issue":"22","key":"key20210719142633_B233","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"ARCTICInvestigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","unstructured":"233. Collet JP, Cuisset T, Rang\u00e9 G, Cayla G, Elhadad S, Pouillot C, et al; ARCTICInvestigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100-9.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20210719142633_B234","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1527-3466.2007.00027.x","article-title":"Prasugrel: a novel thienopyridine antiplatelet agent: a review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile","volume":"25","author":"Jakubowski","year":"2007","unstructured":"234. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent: a review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25(4):357-74.","journal-title":"Cardiovasc Drug Rev"},{"issue":"21","key":"key20210719142633_B235","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1161\/CIRCULATIONAHA.108.833665","article-title":"Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction","volume":"119","author":"Morrow","year":"2009","unstructured":"235. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. 2009;119(21):2758-64.","journal-title":"Circulation"},{"issue":"16","key":"key20210719142633_B236","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","article-title":"TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38","volume":"118","author":"Wiviott","year":"2008","unstructured":"236. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, et al; TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626-36.","journal-title":"Circulation"},{"issue":"5","key":"key20210719142633_B237","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jacc.2012.03.030","article-title":"Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis","volume":"60","author":"Smith","year":"2012","unstructured":"237. Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol. 2012,31;60(5):388-96.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"key20210719142633_B238","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jama.2012.17312","article-title":"Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy","volume":"308","author":"Gurbel","year":"2012","unstructured":"238. Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012;308(17):1785-94.","journal-title":"JAMA"},{"issue":"4","key":"key20210719142633_B239","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbrc.2012.01.093","article-title":"Ticagrelor induces adenosine triphosphate release from human red blood cells","volume":"418","author":"Ohman","year":"2012","unstructured":"239. Ohman J, Kudira R, Albinsson S, Olde B, Erlinge D. Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun. 2012;418(4):754-8.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"key20210719142633_B240","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","article-title":"Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome","volume":"63","author":"Bonello","year":"2014","unstructured":"240. Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014;63(9):872-7.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"key20210719142633_B241","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCULATIONAHA.118.034790","article-title":"Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI)","volume":"138","author":"Orme","year":"2018","unstructured":"241. Orme RC, Parker WAE, Thomas MR, Judge HM, Baster K, Sumaya W, et.al. Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation 2018;138(13):1290-300.","journal-title":"Circulation"},{"issue":"6","key":"key20210719142633_B242","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCULATIONAHA.118.034489","article-title":"HI-TECH investigators. Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea","volume":"138","author":"Ortega-Paz","year":"2018","unstructured":"242. Ortega-Paz L, Brugaletta S, Ariotti S, Akkerhuis KM, Karagiannis A, Windecker S, et al. HI-TECH investigators. Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea. Circulation 2018;138(6):646-48.","journal-title":"Circulation"},{"issue":"19","key":"key20210719142633_B243","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jacc.2010.11.056","article-title":"PLATO Investigators. The incidence of bradyarrhythmias an clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy","volume":"57","author":"Scirica","year":"2011","unstructured":"243. Scirica BM, Cannon CP, Emanuelsson H, Michelson EL, Harrington RA, Husted S, et al.; PLATO Investigators. The incidence of bradyarrhythmias an clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011;57(19):1908-16.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20210719142633_B244","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000350358","article-title":"Potential benefits of ticagrelor beyond platelet inhibition","volume":"125","author":"Nilsen","year":"2013","unstructured":"244. Nilsen DW. Potential benefits of ticagrelor beyond platelet inhibition. Cardiology. 2013;125(1):31-3.","journal-title":"Cardiology"},{"issue":"24","key":"key20210719142633_B245","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"ames","year":"2010","unstructured":"245. ames S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, et al; PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31(24):3006-16.","journal-title":"Eur Heart J"},{"issue":"11","key":"key20210719142633_B246","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","unstructured":"246. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056-67.","journal-title":"Circulation"},{"issue":"23","key":"key20210719142633_B247","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.111.082727","article-title":"PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack","volume":"125","author":"James","year":"2012","unstructured":"247. James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, et al; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation. 2012;125(23):2914-21.","journal-title":"Circulation"},{"issue":"9711","key":"key20210719142633_B248","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"375","author":"Cannon","year":"2010","unstructured":"248. Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, et al; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283-93.","journal-title":"Lancet"},{"issue":"6","key":"key20210719142633_B249","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"57","author":"Held","year":"2011","unstructured":"249. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57(6):672-84.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"key20210719142633_B250","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/CIRCULATIONAHA.112.124248","article-title":"Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study","volume":"127","author":"Kohli","year":"2013","unstructured":"250. Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, et al. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation. 2013;127(6):673-80.","journal-title":"Circulation"},{"issue":"3","key":"key20210719142633_B251","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/eurheartj\/ehs149","article-title":"PLATO Health Economic Substudy Group. Cost-effectivenessof treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study","volume":"34","author":"Nikolic","year":"2013","unstructured":"251. Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M; PLATO Health Economic Substudy Group. Cost-effectivenessof treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J. 2013;34(3):220-8.","journal-title":"Eur Heart J"},{"issue":"16","key":"key20210719142633_B252","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"ISAR-REACT 5 Trial Investigators Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","unstructured":"252. Sch\u00fcpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, W\u00f6hrle J, et al., ISAR-REACT 5 Trial Investigators Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes N Engl J Med 2019;381(16):1524-34.","journal-title":"N Engl J Med"},{"issue":"10055","key":"key20210719142633_B253","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"ANTARCTIC investigators. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","unstructured":"253. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, et al.ANTARCTIC investigators. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388(10055):2015-22.","journal-title":"Lancet"},{"issue":"17","key":"key20210719142633_B254","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI","volume":"381","author":"Claassens","year":"2019","unstructured":"254. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van \u2018t Hof AWJ, van der Harst P, et al. A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI. N Engl J Med. 2019;381(17):1621-31.","journal-title":"N Engl J Med"},{"issue":"8","key":"key20210719142633_B255","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial","volume":"324","author":"Pereira","year":"2020","unstructured":"255. Pereira NL, Farkouh ME, So D. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial JAMA. 2020;324(8):761-77","journal-title":"JAMA"},{"issue":"1 Suppl","key":"key20210719142633_B256","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and Low-Molecular-Weight Heparin, Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety","volume":"119","author":"Hirsh","year":"2001","unstructured":"256. Hirsh J, Warkentin TE, Shaughnessy SG, Annand SS. Heparin and Low-Molecular-Weight Heparin, Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. Chest. 2001; 119(1 Suppl):64S-94S.","journal-title":"Chest"},{"issue":"7","key":"key20210719142633_B257","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hq0701.093686","article-title":"Mechanism of Action and Pharmacology of Unfractionated Heparin","volume":"21","author":"Hirsh","year":"2001","unstructured":"257. Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of Action and Pharmacology of Unfractionated Heparin. Arterioscler Thromb Vasc Biol. 2001;21(7):1094-96.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"key20210719142633_B258","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1023235926825","article-title":"The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: are view of GUSTO-IIb","volume":"14","author":"Lee","year":"2002","unstructured":"258. Lee MS, Wali AU, Menon V, Berkowitz SD, Thompson TD, Califf RM, et al. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: are view of GUSTO-IIb. J Thromb Thrombolysis 2002;14(2):91\u2013101.","journal-title":"J Thromb Thrombolysis"},{"issue":"15","key":"key20210719142633_B259","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac Ischemic events in unstable angina\/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial","volume":"100","author":"Antman","year":"1999","unstructured":"259. AntmanEM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac Ischemic events in unstable angina\/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100(15):1593\u2013601.","journal-title":"Circulation"},{"issue":"7","key":"key20210719142633_B260","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease","volume":"337","author":"Cohen","year":"1997","unstructured":"260. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, et al. A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease. N Engl J Med. 1997;337(7),447-52.","journal-title":"N Engl J Med"},{"issue":"15","key":"key20210719142633_B261","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the Treatment Effect of Enoxaparin for Unstable angina\/non-Q-wave Myocardial Infarction. TIMI 11B-ESSENCE Meta-Analysis","volume":"100","author":"Antman","year":"1999","unstructured":"261. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the Treatment Effect of Enoxaparin for Unstable angina\/non-Q-wave Myocardial Infarction. TIMI 11B-ESSENCE Meta-Analysis. Circulation. 1999;100(15), 1602\u20138.","journal-title":"Circulation"},{"issue":"1","key":"key20210719142633_B262","first-page":"45","article-title":"Enoxaparin VS unfractionated heparin in high risk patients with non-ST-segment elevation acute coronary syndromes managed with na intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","unstructured":"262. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. Enoxaparin VS unfractionated heparin in high risk patients with non-ST-segment elevation acute coronary syndromes managed with na intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292(1):45\u201354.","journal-title":"JAMA"},{"issue":"5","key":"key20210719142633_B263","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.CIR.103.5.658","article-title":"Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris","volume":"103","author":"Collet","year":"2001","unstructured":"263. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001;103(5):658\u201363.","journal-title":"Circulation"},{"issue":"12","key":"key20210719142633_B264","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0300-9084(03)00078-6","article-title":"1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site","volume":"85","author":"Petitou","year":"2003","unstructured":"264. Petitou M, Casu B, Lindahl U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie. 2003;85(12):83\u20139.","journal-title":"Biochimie"},{"key":"key20210719142633_B265","first-page":"e152S","volume-title":"Chest","author":"Holbrook","year":"2012","unstructured":"265. Holbrook A, Schulman S, Witt DM, Vandnivick PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S\u2013e184S.","edition":"9th ed"},{"key":"key20210719142633_B266","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/bs.pmbts.2019.02.004","article-title":"The clinical use of Fondaparinux: A synthetic heparin pentasaccharide","volume":"163","author":"Zhang","year":"2019","unstructured":"266. Zhang Y, Zhang M, Tan L, Pan N, Zhang L. The clinical use of Fondaparinux: A synthetic heparin pentasaccharide. Prog Mol Biol Transl Sci. 2019;163:41\u201353.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"18","key":"key20210719142633_B267","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2007.07.042","article-title":"Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Results From the OASIS-5 Trial","volume":"50","author":"Mehta","year":"2007","unstructured":"267. Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L,Faxon DP, et al. Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Results From the OASIS-5 Trial. J Am Coll Cardiol 2007;50(18):1742-51","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"key20210719142633_B268","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","unstructured":"268. Gibson CM, Mehran R, Bode C, Halpecin J, Verheugt FW, Goose P, Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423\u201334.","journal-title":"N Engl J Med"},{"issue":"25","key":"key20210719142633_B269","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","unstructured":"269. Cannon CP, Bhatt DL, Oldgren J, Thomas L, Ansell J, Fonarow GC, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(25):1513\u201324.","journal-title":"N Engl J Med"},{"issue":"16","key":"key20210719142633_B270","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","unstructured":"270. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al Antithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380(16):1509-24.","journal-title":"N Engl J Med"},{"issue":"10206","key":"key20210719142633_B271","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based Versus Vitamin K Antagonist-Based Antithrombotic Regimen After Successful Coronary Stenting in Patients With Atrial Fibrillation (ENTRUST-AF PCI): A Randomised, Open-Label, Phase 3b Trial","volume":"394","author":"Vranckx","year":"2019","unstructured":"271. Vranckx P, Valgimigli M, Eckardt L, Tijsssen J, Lewatter T, Gargiuo G, et al. Edoxaban-based Versus Vitamin K Antagonist-Based Antithrombotic Regimen After Successful Coronary Stenting in Patients With Atrial Fibrillation (ENTRUST-AF PCI): A Randomised, Open-Label, Phase 3b Trial. Lancet, 2019;394 (10206), 1335-43.","journal-title":"Lancet"},{"issue":"5","key":"key20210719142633_B272","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal Antithrombotic Regimens for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: an Updated Network Meta-analysis","volume":"5","author":"Lopes","year":"2020","unstructured":"272. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Optimal Antithrombotic Regimens for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: an Updated Network Meta-analysis. JAMA Cardiol. 2020;5(5):582-589.","journal-title":"JAMA Cardiol"},{"key":"key20210719142633_B273","first-page":"ehaa575","article-title":"ESC Scientific Document Group, 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","author":"Collet","year":"2020","unstructured":"273. Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al ESC Scientific Document Group, 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2020 Aug 20 ehaa575 [online]","journal-title":"Eur Heart J"},{"key":"key20210719142633_B274","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","unstructured":"274. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et.al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495\u201315042.","journal-title":"N Engl J Med"},{"issue":"14","key":"key20210719142633_B275","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","unstructured":"275. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-9.","journal-title":"N Engl J Med"},{"issue":"9326","key":"key20210719142633_B276","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholsterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Collaborative Group","year":"2002","unstructured":"276. Heart Protection Collaborative Group. MRC\/BHF Heart Protection Study of cholsterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.","journal-title":"Lancet"},{"issue":"5","key":"key20210719142633_B277","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/2048872616647705","article-title":"Excess Mortality and Guideline-Indicated Care Following non-ST-elevation Myocardial Infarction","volume":"6","author":"Dondo","unstructured":"277. Dondo TB, Hall M, Timmis AD, Gilthorpe MS, Alabas AO, Batin PD, et al. Excess Mortality and Guideline-Indicated Care Following non-ST-elevation Myocardial Infarction. Eur Heart J Acute Cardiovasc Care, 2107;6 (5), 412-20.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"6 Supl.1","key":"key20210719142633_B278","first-page":"1","article-title":"Diretriz brasileira baseada em evid\u00eancias sobre preven\u00e7\u00e3o de doen\u00e7as cardiovasculares em pacientes com diabetes: posicionamento da Sociedade Brasileira de Diabetes (SBD), da Sociedade Brasileira de Cardiologia (SBC) e da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)","volume":"109","author":"Faludi","year":"2017","unstructured":"278. Faludi AA, Izar MCO, Saraiva JFK, Bianco HT, Chacra APM, Bertoluci MC et al. Diretriz brasileira baseada em evid\u00eancias sobre preven\u00e7\u00e3o de doen\u00e7as cardiovasculares em pacientes com diabetes: posicionamento da Sociedade Brasileira de Diabetes (SBD), da Sociedade Brasileira de Cardiologia (SBC) e da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM). Arq Bras Cardiol. 2017; 109(6 Supl.1):1-31","journal-title":"Arq Bras Cardiol"},{"key":"key20210719142633_B279","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","unstructured":"279. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et.al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-97.","journal-title":"N Engl J Med"},{"issue":"13","key":"key20210719142633_B280","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.2018.2444","article-title":"Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome","volume":"319","author":"Berwanger","year":"2018","unstructured":"280. Berwanger O, Santucci EV, de Barros e Silva PGM, Jesu\u00edno IA, Damiani LP, Barbosa LM, et al. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome. JAMA. 2018;319(13):1331-40.","journal-title":"JAMA"},{"issue":"3","key":"key20210719142633_B281","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of na angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","unstructured":"281. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of na angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53. Erratum in N Engl J Med. 2000;342(10):748 Erratum: N Engl J Med. 2000;342(18):1376.","journal-title":"N Engl J Med"},{"issue":"9386","key":"key20210719142633_B282","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","unstructured":"282. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362(9386):782-8.","journal-title":"Lancet"},{"issue":"2","key":"key20210719142633_B283","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/ehjcvp\/pvy005","article-title":"Trends in Optimal Medical Therapy Prescription and Mortality After Admission for Acute Coronary Syndrome: A 9-year Experience in a Real-World Setting","volume":"4","author":"Hoedemaker","year":"2018","unstructured":"283. Hoedemaker NPG, Damman P, Ottervanger JP, Dambrink JHE, Gosselink ATM, Kedhi E, et.al. Trends in Optimal Medical Therapy Prescription and Mortality After Admission for Acute Coronary Syndrome: A 9-year Experience in a Real-World Setting. Eur Heart J Cardiovasc Pharmacother,2018; 4(2):102-10.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"14","key":"key20210719142633_B284","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","unstructured":"284. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348(14):1309-21. Erratum in: N Engl J Med. 2003; 348(22):2271.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20210719142633_B285","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.acvd.2014.01.010","article-title":"Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial","volume":"107","author":"Carillo","year":"2014","unstructured":"285. Carillo S, Zhang Y, Fay R, Angioi M, Vincent J, Sutradhor SC, et al. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial. Arch Cardiovasc Dis. 2014 Mar;107(3):149-57.","journal-title":"Arch Cardiovasc Dis"},{"issue":"10","key":"key20210719142633_B286","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","unstructured":"286. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17.","journal-title":"N Engl J Med"},{"issue":"14","key":"key20210719142633_B287","first-page":"1883","article-title":"American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). ACC\/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology\/American Heart AssociationTask Force on Practice Guidelines (Committee to Update the 1997 ExerciseTesting Guidelines)","volume":"106","author":"Gibbons","year":"2002","unstructured":"287. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, et al; American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). ACC\/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology\/American Heart AssociationTask Force on Practice Guidelines (Committee to Update the 1997 ExerciseTesting Guidelines). Circulation. 2002;106(14):1883-92.","journal-title":"Circulation"},{"issue":"20","key":"key20210719142633_B288","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1161\/01.CIR.0000165556.44271.BE","article-title":"American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care); Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group; Society of Chest Pain Centers. Practical implementation of the guidelines for unstable angina\/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Councilon Clinical Cardiology (Subcommittee on Acute Cardiac Care), Councilon Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group,in Collaboration With the Society of Chest Pain Centers","volume":"111","author":"Gibler","year":"2005","unstructured":"288. Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, et al; American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care); Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group; Society of Chest Pain Centers. Practical implementation of the guidelines for unstable angina\/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Councilon Clinical Cardiology (Subcommittee on Acute Cardiac Care), Councilon Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group,in Collaboration With the Society of Chest Pain Centers. Circulation. 2005;111(20):2699-710.","journal-title":"Circulation"},{"issue":"5","key":"key20210719142633_B289","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.pcad.2004.02.001","article-title":"Early exercise testing in the management of low risk patients in chest pain centers","volume":"46","author":"Amsterdam","year":"2004","unstructured":"289. Amsterdam EA, Kirk JD, Diercks DB, Lewis WR, Turnipseed SD. Early exercise testing in the management of low risk patients in chest pain centers. Prog Cardiovasc Dis. 2004;46(5):438-52.","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"key20210719142633_B290","doi-asserted-by":"crossref","first-page":"793","DOI":"10.7326\/0003-4819-106-6-793","article-title":"Exercise treadmill score for predicting prognosis in coronary artery disease","volume":"106","author":"Mark","year":"1987","unstructured":"290. Mark DB, Hlatky MA, Harrell FE Jr, Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med. 1987;106(6):793-800.","journal-title":"Ann Intern Med"},{"issue":"12","key":"key20210719142633_B291","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/01.CIR.102.12.1463","article-title":"Safety and utility of exercise testing in emergency room chest pain centers: an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association","volume":"102","author":"Stein","year":"2000","unstructured":"291. Stein RA, Chaitman BR, Balady GJ, Fleg JL, Limacher MC, Pina IL, et al. Safety and utility of exercise testing in emergency room chest pain centers: an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation. 2000;102(12):1463-7.","journal-title":"Circulation"},{"issue":"1","key":"key20210719142633_B292","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF01797676","article-title":"Should the exercise test (ET) be performed at discharge or one month later after an episode of unstable angina or non-Q-wave myocardial infarction?","volume":"7","author":"Larsson","year":"1991","unstructured":"292. Larsson H, Areskog M, Areskog NH, Nylander E, Nyman I, Swahn E, et al. Should the exercise test (ET) be performed at discharge or one month later after an episode of unstable angina or non-Q-wave myocardial infarction? Int J Card Imaging. 1991;7(1):7-14.","journal-title":"Int J Card Imaging"},{"issue":"1","key":"key20210719142633_B293","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.annemergmed.2009.01.006","article-title":"The limited utility of routine cardiac stress testing in emergency department chest pain patients younger than 40 years","volume":"54","author":"Hermann","year":"2009","unstructured":"293. Hermann LK, Weingart SD, Duvall WL, Henzlova MJ. The limited utility of routine cardiac stress testing in emergency department chest pain patients younger than 40 years. Ann Emerg Med. 2009;54(1):12-6.","journal-title":"Ann Emerg Med"},{"issue":"2","key":"key20210719142633_B294","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.annemergmed.2019.01.027","article-title":"Evaluation of Outpatient Cardiac Stress Testing After Emergency Department Encounters for Suspected Acute Coronary Syndrome","volume":"74","author":"Natsui","year":"2019","unstructured":"294. Natsui S, Sun BC, Shen E, Wu YL, Redberg RF, Lee MS, et al. Evaluation of Outpatient Cardiac Stress Testing After Emergency Department Encounters for Suspected Acute Coronary Syndrome. Ann Emerg Med. 2019 Aug;74(2):216-23.","journal-title":"Ann Emerg Med"},{"issue":"3 Suppl","key":"key20210719142633_B295","first-page":"I85","article-title":"Value of regional wall motion abnormality in the emergency room diagnosis of acute myocardial infarction: a prospective study using two-dimensional echocardiography","volume":"84","author":"Sabia","year":"1991","unstructured":"295. Sabia P, Afrookteh A, Touchstone DA, Keller MW, Esquivel L, Kaul S. Value of regional wall motion abnormality in the emergency room diagnosis of acute myocardial infarction: a prospective study using two-dimensional echocardiography. Circulation. 1991;84(3 Suppl):I85-92.","journal-title":"Circulation"},{"issue":"10","key":"key20210719142633_B296","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/clc.4960211006","article-title":"Improved risk stratification in unstable angina: identification of patients at low risk for in hospital cardiac events by admission echocardiography","volume":"21","author":"Stein","year":"1998","unstructured":"296. Stein JH, Neumann A, Preston LM, VandenBerg BJ, Parrillo JE, Calvin JE, et al. Improved risk stratification in unstable angina: identification of patients at low risk for in hospital cardiac events by admission echocardiography. Clin Cardiol. 1998;21(10):725-30.","journal-title":"Clin Cardiol"},{"issue":"2","key":"key20210719142633_B297","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/01.CIR.65.2.323","article-title":"Immediate diagnosis of acute myocardial infarction by two-dimensional echocardiography","volume":"65","author":"Horowitz","year":"1982","unstructured":"297. Horowitz RS, Morganroth J, Parrotto C, Chen CC, Soffer J, Pauletto FJ. Immediate diagnosis of acute myocardial infarction by two-dimensional echocardiography. Circulation. 1982;65(2):323-9.","journal-title":"Circulation"},{"issue":"5","key":"key20210719142633_B298","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0196-0644(98)70200-8","article-title":"Early echocardiography can predict cardiac events in emergency department patients with chest pain","volume":"31","author":"Kontos","year":"1998","unstructured":"298. Kontos MC, Arrowood JA, Paulsen WH, Nixon JV. Early echocardiography can predict cardiac events in emergency department patients with chest pain. Ann Emerg Med. 1998;31(5):550-7.","journal-title":"Ann Emerg Med"},{"issue":"1","key":"key20210719142633_B299","first-page":"135","article-title":"Position Statement on Indications of Echocardiography in Adults - 2019","volume":"113","author":"Barberato","year":"2019","unstructured":"299. Barberato SH, Romano MMD, Beck ALS, Rodrigues ACT, Almeida ALC, Assun\u00e7\u00e3o BMBL, et al. Position Statement on Indications of Echocardiography in Adults - 2019. Arq Bras Cardiol. 2019; 113(1):135-81.","journal-title":"Arq Bras Cardiol"},{"issue":"Suppl 2","key":"key20210719142633_B300","first-page":"11","article-title":"Brazilian Society of Cardiology. [Guideline for indication and utilization of echocardiography in clinical practice]","volume":"82","author":"Campos","year":"2004","unstructured":"300. Campos FO, Zielinsky P, Ortiz J, Maciel BC, Andrade JL, Mathias W Jr, et al; Brazilian Society of Cardiology. [Guideline for indication and utilization of echocardiography in clinical practice]. Arq Bras Cardiol. 2004;82(Suppl 2):11-34.","journal-title":"Arq Bras Cardiol"},{"issue":"3","key":"key20210719142633_B301","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/echo.14275","article-title":"Predictive value of global and territorial longitudinal strain imaging in detecting significant coronary artery disease inpatients with myocardial infarction without persistent ST-segment elevation","volume":"36","author":"Atici","year":"2019","unstructured":"301. Atici A, Ali Barman H, Durmaz E, Demir K, Cakmak R, Tugrul S, et al. Predictive value of global and territorial longitudinal strain imaging in detecting significant coronary artery disease inpatients with myocardial infarction without persistent ST-segment elevation. Echocardiography. 2019; 36(3):425-622.","journal-title":"Echocardiography"},{"issue":"6","key":"key20210719142633_B302","doi-asserted-by":"crossref","first-page":"451","DOI":"10.7326\/0003-4819-134-6-200103200-00009","article-title":"Recovery of venricular function after myocardial infarction in the reperfusion era: The healing and early after local therapy study","volume":"134","author":"Solomon","year":"2001","unstructured":"302. Solomon SD, Glynn RJ, Greaves S, Ajani U, Rouleau JL, Menapace RF, et al. Recovery of venricular function after myocardial infarction in the reperfusion era: The healing and early after local therapy study. Ann Intern Med. 2001; 134(6): 451 - 8.","journal-title":"Ann Intern Med"},{"issue":"8","key":"key20210719142633_B303","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.echo.2016.03.002","article-title":"Detectionof Obstructive Coronary Artery Disease Using Peak Systolic Global Longitudinal Strain Derived by Two-Dimensional Speckle-Tracking: A Systematic Review and Meta-Analysis","volume":"29","author":"Liou","year":"2016","unstructured":"303. Liou K, Negishi K, Ho S, Russell EA, Cranney G, Ooi SY. Detectionof Obstructive Coronary Artery Disease Using Peak Systolic Global Longitudinal Strain Derived by Two-Dimensional Speckle-Tracking: A Systematic Review and Meta-Analysis. J Am Soc Echocardiogr.2016;29(8):724-35 e4.","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"key20210719142633_B304","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10554-017-1269-x","article-title":"Two-dimensional speckle-tracking global longitudinal strain in high-sensitivity troponin-negative low-risk patients with unstable angina: a \u201cresting ischemia test\u201d?","volume":"34","author":"Marques-Alves","year":"2017","unstructured":"304. Marques-Alves P, Espirito-Santo N, Baptista R, Teixeira R, Martins R, Gon\u00e7alvrs F, et al. Two-dimensional speckle-tracking global longitudinal strain in high-sensitivity troponin-negative low-risk patients with unstable angina: a \u201cresting ischemia test\u201d? Int J Cardiovasc Imaging. 2017; 34(4):561-8.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"5","key":"key20210719142633_B305","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.echo.2014.01.019","article-title":"Early assessment of strain echocardiography can accurately exclude significant coronary artery stenosis in suspected non-ST-segment elevation acute coronary syndrome","volume":"27","author":"Dahlslett","year":"2014","unstructured":"305. Dahlslett T, Karlsen S, Grenne B, Eek C, Sjoli B, Skustad H, et al. Early assessment of strain echocardiography can accurately exclude significant coronary artery stenosis in suspected non-ST-segment elevation acute coronary syndrome. J Am Soc Echocardiogr. 2014;27(5):512\u20139.","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"key20210719142633_B306","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.echo.2017.11.013","article-title":"Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update","volume":"31","author":"Porter","year":"2018","unstructured":"306. Porter TR, Mulvagh SL, Abdelmoneim SS, Becher H, Belcik JT, Bierig M, et.al. Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update. J Am Soc Echocardiogr. 2018; 31(3):241-74.","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"key20210719142633_B307","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2019.07.001","article-title":"Guidelines for Performance, Interpretation, and Application of Stress Echocardiography in Ischemic Heart Disease: From the American Society of Echocardiography","volume":"33","author":"Pellikka","year":"2020","unstructured":"307. Pellikka PA, Olson AA, Chaudhry FA, Chen MH, Marshall JE, Porter TR, Sawada SG, Guidelines for Performance, Interpretation, and Application of Stress Echocardiography in Ischemic Heart Disease: From the American Society of Echocardiography. J Am Soc Echocardiogr.2020;33(1):1-41.","journal-title":"J Am Soc Echocardiogr"},{"issue":"13","key":"key20210719142633_B308","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/euhj.2001.3072","article-title":"Exercise-electrocardiography and\/or pharmacological stress echocardiography for non-invasive risk stratification early after uncomplicated myocardial infarction: a prospective international large scale multicentre study","volume":"23","author":"Sicari","year":"2002","unstructured":"308. Sicari R, Landi P, Picano E, Pirelli S, Chiaranda G, Previtali M, et al. Exercise-electrocardiography and\/or pharmacological stress echocardiography for non-invasive risk stratification early after uncomplicated myocardial infarction: a prospective international large scale multicentre study. Eur Heart J. 2002;23(13):1030-7.","journal-title":"Eur Heart J"},{"issue":"38","key":"key20210719142633_B309","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","unstructured":"309. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003.","journal-title":"Eur Heart J"},{"issue":"8931","key":"key20210719142633_B310","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/S0140-6736(94)90508-8","article-title":"Safety and tolerability of dobutamine-atropine stress echocardiography: a prospective, multicentre study. Echo Dobutamine International Cooperative Study Group","volume":"344","author":"Picano","year":"1994","unstructured":"310. Picano E, Mathias W Jr, Pingitore A, Bigi R, Previtali M. Safety and tolerability of dobutamine-atropine stress echocardiography: a prospective, multicentre study. Echo Dobutamine International Cooperative Study Group. Lancet. 1994;344(8931):1190-2.","journal-title":"Lancet"},{"issue":"9","key":"key20210719142633_B311","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.echo.2004.05.016","article-title":"Value of myocardial contrast echocardiography for predicting left ventricular remodeling and segmental functional recovery after anterior wall acute myocardial infarction","volume":"17","author":"Caldas","year":"2004","unstructured":"311. Caldas MA, Tsutsui JM, Kowatsch I, Andrade JL, Nicolau JC, Ramires JF, et al. Value of myocardial contrast echocardiography for predicting left ventricular remodeling and segmental functional recovery after anterior wall acute myocardial infarction. J Am Soc Echocardiogr. 2004;17(9):923-32.","journal-title":"J Am Soc Echocardiogr"},{"issue":"2","key":"key20210719142633_B312","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1540-8175.2002.00109.x","article-title":"Endocardial borderdeline action during dobutamine infusion using contrast echocardiography","volume":"19","author":"Mathias","year":"2002","unstructured":"312. Mathias W Jr, Arruda AL, Andrade JL, Filho OC, Porter TR. Endocardial borderdeline action during dobutamine infusion using contrast echocardiography. Echocardiography. 2002;19(2):109-14.","journal-title":"Echocardiography"},{"issue":"8","key":"key20210719142633_B313","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.echo.2014.05.011","article-title":"Guidelines for the cardiac sonographer in the performance of contrast echocardiography: a focused update from the American Society of Echocardiography","volume":"27","author":"Porter","year":"2014","unstructured":"313. Porter TR, Abdelmoneim S, Belcik JT, McCulloch ML, Mulvagh SL, Olson JJ, et al. Guidelines for the cardiac sonographer in the performance of contrast echocardiography: a focused update from the American Society of Echocardiography. J Am Soc Echocardiogr. 2014;27(8):797-810.","journal-title":"J Am Soc Echocardiogr"},{"issue":"8","key":"key20210719142633_B314","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jacc.2005.01.024","article-title":"Safety of dobutamine stress real-time myocardial contrast echocardiography","volume":"45","author":"Tsutsui","year":"2005","unstructured":"314. Tsutsui JM, Elhendy A, Xie F, O\u2019Leary EL, McGrain AC, Porter TR. Safety of dobutamine stress real-time myocardial contrast echocardiography. J Am Coll Cardiol. 2005;45(8):1235-42.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"key20210719142633_B315","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1540-8175.2005.40037.x","article-title":"Diagnostic accuracy and prognostic value of dobutamine stress myocardial contrast echocardiography in patients with suspected acute coronary syndromes","volume":"22","author":"Tsutsui","year":"2005","unstructured":"315. Tsutsui JM, Xie F, O\u2019Leary EL, Elhendy A, Anderson JR, McGrain AC, et al. Diagnostic accuracy and prognostic value of dobutamine stress myocardial contrast echocardiography in patients with suspected acute coronary syndromes. Echocardiography. 2005;22(6):487-95.","journal-title":"Echocardiography"},{"issue":"1","key":"key20210719142633_B316","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nuclcard.2004.11.006","article-title":"Evaluation of the unstable angina patient in 2005: is there still a role for non invasive risk stratification?","volume":"12","author":"Brown","year":"2005","unstructured":"316. Brown KA. Evaluation of the unstable angina patient in 2005: is there still a role for non invasive risk stratification? J Nucl Cardiol. 2005;12(1):9-11.","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"key20210719142633_B317","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0167-5273(94)90175-9","article-title":"Noninvasive testing in the diagnosis and management of unstable angina","volume":"47","author":"Amanullah","year":"1994","unstructured":"317. Amanullah AM. Noninvasive testing in the diagnosis and management of unstable angina. Int J Cardiol. 1994;47(2):95-103.","journal-title":"Int J Cardiol"},{"key":"key20210719142633_B318","first-page":"490","volume-title":"Nuclear cardiology: stateoftheartand future directions","author":"Miller","year":"1999","unstructured":"318. Miller DD. Risk stratification in unstable angina pectoris. In: Zaret BL, Beller GA. (eds) Nuclear cardiology: stateoftheartand future directions. Saint Louis: Mosby Inc; 1999. p. 490-9."},{"issue":"4","key":"key20210719142633_B319","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0002-9149(99)80072-1","article-title":"Exercise technetium-99m myocardial tomography for the risk stratification of men with medically treated unstable angina pectoris","volume":"76","author":"Stratmann","year":"1995","unstructured":"319. Stratmann HG, Younis LT, Wittry MD, Amato M, Miller DD. Exercise technetium-99m myocardial tomography for the risk stratification of men with medically treated unstable angina pectoris. Am J Cardiol. 1995;76(4):236-40.","journal-title":"Am J Cardiol"},{"issue":"17","key":"key20210719142633_B320","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/0002-9149(88)90253-6","article-title":"Usefulness of exercise electrocardiography and thallium scintigraphy in unstable angina pectoris in predicting the extent and severity of coronary artery disease","volume":"62","author":"Freeman","year":"1988","unstructured":"320. Freeman MR, Chisholm RJ, Armstrong PW. Usefulness of exercise electrocardiography and thallium scintigraphy in unstable angina pectoris in predicting the extent and severity of coronary artery disease. Am J Cardiol. 1988;62(17):1164-70. Erratum in: Am J Cardiol 1989;63(5):392.","journal-title":"Am J Cardiol"},{"issue":"1 Pt 1","key":"key20210719142633_B321","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0002-8703(91)90952-E","article-title":"Dipyridamole perfusion scintigraphy: the experience with its application in one hundred seventy patients with known or suspected unstable angina","volume":"121","author":"Zhu","year":"1991","unstructured":"321. Zhu YY, Chung WS, Botvinick EH, Dae MW, Lim AD, Ports TA, et al. Dipyridamole perfusion scintigraphy: the experience with its application in one hundred seventy patients with known or suspected unstable angina. Am Heart J. 1991;121(1 Pt 1):33-43.","journal-title":"Am Heart J"},{"issue":"5","key":"key20210719142633_B322","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0735-1097(91)90829-X","article-title":"Prognosticvalueof thallium-201 myocardial perfusion imaging in patients with unstable angina who respond to medical treatment","volume":"17","author":"Brown","year":"1991","unstructured":"322. Brown KA. Prognosticvalueof thallium-201 myocardial perfusion imaging in patients with unstable angina who respond to medical treatment. J Am Coll Cardiol. 1991;17(5):1053-7.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20210719142633_B323","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/hrt.59.2.184","article-title":"Prognosis and thallium-201 scintigraphy in patients admitted with chest pain without confirmed acute myocardial infarction","volume":"59","author":"Madsen","year":"1988","unstructured":"323. Madsen JK, Stubgaard M, Utne HE, Hansen JF, van Duijvendijk K, Reiber JH, et al. Prognosis and thallium-201 scintigraphy in patients admitted with chest pain without confirmed acute myocardial infarction. Br Heart J. 1988;59(2):184-9.","journal-title":"Br Heart J"},{"issue":"2","key":"key20210719142633_B324","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.jacc.2007.09.006","article-title":"F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: A randomized, controlled trial (PARR-2)","volume":"50","author":"Beanlands","year":"2007","unstructured":"324. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: A randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50(2):2002\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"key20210719142633_B325","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jacc.2011.01.065","article-title":"Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia","volume":"58","author":"Ziadi","year":"2011","unstructured":"325. Ziadi MC, Dekemp RA, Williams KA, Guo A, Chow BJ, Renaud JM, et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol.2011;58(7):740-8.","journal-title":"J Am Coll Cardiol"},{"key":"key20210719142633_B326","article-title":"Quantification of Myocardial Flow Reserve Using aGamma Camera With Solid-State Cadmium-Zinc-Telluride Detectors: Relation to Angiographic Coronary Artery Disease","author":"de Souza","year":"2019","unstructured":"326. de Souza ACDAH, Gon\u00e7alves BKD, Tedeschi AL, Lima RSL. Quantification of Myocardial Flow Reserve Using aGamma Camera With Solid-State Cadmium-Zinc-Telluride Detectors: Relation to Angiographic Coronary Artery Disease. J Nucl Cardiol. 2019; Jun 20. Doi 10.1007\/s12350-019-01775-z. ahead of print","journal-title":"J Nucl Cardiol"},{"issue":"22","key":"key20210719142633_B327","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/CIR.0b013e3181d44a8f","article-title":"American College of Cardiology Foundation Task Force on Expert Consensus Documents. ACCF\/ACR\/AHA\/NASCI\/SCMR 2010 expert consensus documenton cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents","volume":"121","author":"Hundley","year":"2010","unstructured":"327. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents. ACCF\/ACR\/AHA\/NASCI\/SCMR 2010 expert consensus documenton cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;121(22):2462-508.","journal-title":"Circulation"},{"issue":"6","key":"key20210719142633_B328","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/01.CIR.99.6.763","article-title":"Non invasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography","volume":"99","author":"Nagel","year":"1999","unstructured":"328. Nagel E, Lehmkuhl HB, Bocksch W, Klein C, Vogel U, Frantz E, et al. Non invasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation. 1999;99(6):763-70.","journal-title":"Circulation"},{"issue":"19","key":"key20210719142633_B329","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jacc.2011.12.040","article-title":"Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and p\u00f3sitron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis","volume":"59","author":"Jaarsma","year":"2012","unstructured":"329. Jaarsma C, Leiner T, Bekkers SC, Crijns HJ, Wildberger JE, Nagel E, et al. Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and p\u00f3sitron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis. J Am Coll Cardiol. 2012;59(19):1719-28.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"key20210719142633_B330","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/eurheartj\/ehs022","article-title":"MR-IMPACT Investigators. MR-IMPACT II: Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary artery diseaseTrial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease: a comparative multicentre, multivendor trial","volume":"34","author":"Schwitter","year":"2013","unstructured":"330. Schwitter J, Wacker CM, Wilke N, Al-Saadi N, Sauer E, Huettle K, et al; MR-IMPACT Investigators. MR-IMPACT II: Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary artery diseaseTrial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease: a comparative multicentre, multivendor trial. Eur Heart J. 2013;34(10):775-81.","journal-title":"Eur Heart J"},{"issue":"22","key":"key20210719142633_B331","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/CIRCULATIONAHA.109.872358","article-title":"Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease","volume":"120","author":"Watkins","year":"2009","unstructured":"331. Watkins S, McGeoch R, Lyne J, Steedman T, Good R, McLaughlin MJ, et al. Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease. Circulation. 2009;120(22):2207-13.","journal-title":"Circulation"},{"issue":"14","key":"key20210719142633_B332","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1161\/CIRCULATIONAHA.108.812503","article-title":"Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease","volume":"120","author":"Steel","year":"2009","unstructured":"332. Steel K, Broderick R, Gandla V, Larose E, Resnic F, Jerosch-Herold M, et al. Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Circulation. 2009;120(14):1390-400.","journal-title":"Circulation"},{"issue":"20","key":"key20210719142633_B333","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJM200011163432003","article-title":"The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction","volume":"343","author":"Kim","year":"2000","unstructured":"333. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343(20):1445-53.","journal-title":"N Engl J Med"},{"issue":"10","key":"key20210719142633_B334","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/hc3501.096798","article-title":"Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function","volume":"104","author":"Choi","year":"2001","unstructured":"334. Choi KM, Kim RJ, Gubernikoff G, Vargas JD, Parker M, Judd RM. Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation. 2001;104(10):1101-7.","journal-title":"Circulation"},{"issue":"9355","key":"key20210719142633_B335","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0140-6736(03)12389-6","article-title":"Contrast-enhanced MRI androutine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial Myocardial infarcts: an imaging study","volume":"361","author":"Wagner","year":"2003","unstructured":"335. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, et al. Contrast-enhanced MRI androutine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial Myocardial infarcts: an imaging study. Lancet. 2003;361(9355):374-9.","journal-title":"Lancet"},{"issue":"21","key":"key20210719142633_B336","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1161\/CIRCULATIONAHA.109.852517","article-title":"Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction","volume":"120","author":"Cheong","year":"2009","unstructured":"336. Cheong BY, Muthupillai R, Wilson JM, Sung A, Huber S, Amin S, et al. Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction. Circulation. 2009;120(21):2069-76.","journal-title":"Circulation"},{"issue":"9249","key":"key20210719142633_B337","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0140-6736(00)03567-4","article-title":"Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q wave myocardial infarction","volume":"357","author":"Wu","year":"2001","unstructured":"337. Wu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q wave myocardial infarction. Lancet. 2001;357(9249):21-8.","journal-title":"Lancet"},{"issue":"5","key":"key20210719142633_B338","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/CIRCULATIONAHA.107.723262","article-title":"Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: na international, multicenter, double-blinded, randomized trial","volume":"117","author":"Kim","year":"2008","unstructured":"338. Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, et al. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: na international, multicenter, double-blinded, randomized trial. Circulation.2008;117(5):629-37.","journal-title":"Circulation"},{"issue":"1","key":"key20210719142633_B339","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2009.06.059","article-title":"Cardiovascular magneticresonance in patients with myocardial infarction: current and emerging applications","volume":"55","author":"Kim","year":"2009","unstructured":"339. Kim HW, Farzaneh-Far A, Kim RJ. Cardiovascular magneticresonance in patients with myocardial infarction: current and emerging applications. J Am Coll Cardiol. 2009;55(1):1-16.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"key20210719142633_B340","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jacc.2014.06.1194","article-title":"Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction","volume":"64","author":"Eitel","year":"2014","unstructured":"340. Eitel I, de Waha S, W\u00f6hrle J, Fuernau G, Lurz P, Pauschinger M, et al. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2014 Sep 23;64(12):1217-26.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"key20210719142633_B341","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/2012.jama.11089","article-title":"Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults","volume":"308","author":"Schelbert","year":"2012","unstructured":"341. Schelbert EB, Cao JJ, Sigurdsson S, Aspelund T, Kellman P, Aletras AH, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA. 2012;308(9):890-6.","journal-title":"JAMA"},{"issue":"8","key":"key20210719142633_B342","article-title":"Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or Symptoms of coronary artery disease","volume":"114","author":"Kwong","year":"2006","unstructured":"342. Kwong RY, Chan AK, Brown KA, Chan CW, Reynolds HG, Tsang S, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or Symptoms of coronary artery disease. Circulation. 2006;113(23):2733-43. Erratum in Circulation. 2006;114(8):e365.","journal-title":"Circulation"},{"issue":"8","key":"key20210719142633_B343","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/01.CIR.97.8.765","article-title":"Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction","volume":"97","author":"Wu","year":"1998","unstructured":"343. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation.1998;97(8):765-72.","journal-title":"Circulation"},{"issue":"19","key":"key20210719142633_B344","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.jacc.2009.07.027","article-title":"Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging","volume":"54","author":"Kelle","year":"2009","unstructured":"344. Kelle S, Roes SD, Klein C, Kokocinski T, de Roos A, Fleck E, et al. Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol. 2009;54(19):1770-7.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20210719142633_B345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228736","article-title":"Prognostic value of the myocardial salvage index measured by T2-weighted and T1-weighted late gadolinium enhancement magnetic resonance imaging after ST-segment elevation myocardial infarction: A systematic review and meta-regression analysis","volume":"15","author":"Kendziora","year":"2020","unstructured":"345. Kendziora B, Dewey M. Prognostic value of the myocardial salvage index measured by T2-weighted and T1-weighted late gadolinium enhancement magnetic resonance imaging after ST-segment elevation myocardial infarction: A systematic review and meta-regression analysis. PLoS One. 2020 Feb 13;15(2):e0228736.","journal-title":"PLoS One"},{"issue":"23","key":"key20210719142633_B346","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.jacc.2008.02.064","article-title":"Microvascular obstruction the final frontier for a complete myocardial reperfusion","volume":"51","author":"Rochitte","year":"2008","unstructured":"346. Rochitte CE. Microvascular obstruction the final frontier for a complete myocardial reperfusion. J Am Coll Cardiol. 2008;51(23):2239-40.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20210719142633_B347","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1532-429X-14-46","article-title":"Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance","volume":"14","author":"Klug","year":"2012","unstructured":"347. Klug G, Mayr A, Schenk S, Esterhammer R, Schocke M, Nocker M, et al. Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14(1):46.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"15","key":"key20210719142633_B348","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/eurheartj\/ehi258","article-title":"Delayed enhancement cardiovascular magneticresonance assessment of non ischaemic cardiomyopathies","volume":"26","author":"Mahrholdt","year":"2005","unstructured":"348. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magneticresonance assessment of non ischaemic cardiomyopathies. Eur Heart J. 2005;26(15):1461-74.","journal-title":"Eur Heart J"},{"issue":"17","key":"key20210719142633_B349","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","article-title":"International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper","volume":"53","author":"Friedrich","year":"2009","unstructured":"349. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009;53(17):1475-87.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"key20210719142633_B350","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1002\/jmri.26611","article-title":"State of the Art: Evaluation and Prognostication of Myocarditis Using Cardiac MRI","volume":"49","author":"Gannon","year":"2019","unstructured":"350. Gannon MP, Schaub E, Grines CL, Saba SG. State of the Art: Evaluation and Prognostication of Myocarditis Using Cardiac MRI. J Magn Reson Imaging, 2019;49 (7), e122-e131","journal-title":"J Magn Reson Imaging"},{"issue":"2","key":"key20210719142633_B351","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.hfc.2012.12.011","article-title":"Role of cardiovascular magnetic resonance in takotsubo cardiomyopathy","volume":"9","author":"Athanasiadis","year":"2013","unstructured":"351. Athanasiadis A, Schneider B, Sechtem U. Role of cardiovascular magnetic resonance in takotsubo cardiomyopathy. Heart Fail Clin. 2013;9(2):167-76.","journal-title":"Heart Fail Clin"},{"issue":"13","key":"key20210719142633_B352","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1161\/CIRCULATIONAHA.118.037975","article-title":"Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy","volume":"139","author":"Scally","year":"2019","unstructured":"352. Scally C, Abbas H, Ahearn T, Srinivasan J, Mezincescu A, Rudd A, et al. Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy. Circulation. 2019;139 (13):1581-92.","journal-title":"Circulation"},{"issue":"12","key":"key20210719142633_B353","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4330\/wjc.v11.i12.305","article-title":"Myocardial infarction with non-obstructive coronary arteries: A comprehensive review and future research directions","volume":"11","author":"Vidal-Perez","year":"2019","unstructured":"353. Vidal-Perez R, Abou Jokh Casas C, Agra-Bermejo RM, Alvarez-Alvarez B, Grapsa J, Fontes-Carvalho R, et al. Myocardial infarction with non-obstructive coronary arteries: A comprehensive review and future research directions. World J Cardiol. 2019 Dec 26;11(12):305-15.","journal-title":"World J Cardiol"},{"issue":"3","key":"key20210719142633_B354","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/eurheartj\/ehq409","article-title":"MRI in acute myocardial infarction","volume":"32","author":"Perazzolo Marra","year":"2011","unstructured":"354. Perazzolo Marra M, Lima JA, Iliceto S. MRI in acute myocardial infarction. Eur Heart J. 2011;32(3):284-93.","journal-title":"Eur Heart J"},{"issue":"14","key":"key20210719142633_B355","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jacc.2019.02.018","article-title":"Type 2 Myocardial Infarction: JACC Review Topic of the Week","volume":"73","author":"Sandoval","year":"2019","unstructured":"355. Sandoval Y, Jaffe AS. Type 2 Myocardial Infarction: JACC Review Topic of the Week. J Am Coll Cardiol. 2019 Apr 16;73(14):1846-60.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20210719142633_B356","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ccd.28280","article-title":"Meta\u2010analysis of optimal timing of coronary intervention in nonST\u2010elevation acute coronary syndrome","volume":"95","author":"Barbarawi","year":"2020","unstructured":"356. Barbarawi, M, Kheiri, B, Zayed, Y, Barbarawi O, Chahine A, Haykal T, et al. Meta\u2010analysis of optimal timing of coronary intervention in nonST\u2010elevation acute coronary syndrome. Catheter Cardiovasc Interv. 2020; 95(2): 185\u2013 93.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"key20210719142633_B357","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ehjqcco\/qcw044","article-title":"Timing of percutaneous coronary intervention in patients with non-ST-elevation myocardial infarction: a SWEDEHEART study","volume":"3","author":"Lindholm","year":"2017","unstructured":"357. Lindholm D, Alfredsson J, Anger\u00e5s O, Bohm F, Calais F, Koul S, et al. Timing of percutaneous coronary intervention in patients with non-ST-elevation myocardial infarction: a SWEDEHEART study. Eur Heart J Qual Care Clin Outcomes. 2017;3(1):53\u201060.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"2","key":"key20210719142633_B358","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","unstructured":"358. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC\/EACTS Guidelines on myocardial revascularization Eur Heart J. 2019;40(2): 87-165.","journal-title":"Eur Heart J"},{"issue":"19","key":"key20210719142633_B359","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1616540","article-title":"Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI","volume":"376","author":"G\u00f6tberg","year":"2017","unstructured":"359. G\u00f6tberg M, Christiansen EH, Gudmundsdottir I J, Sandhall L, Danielewicz M, Jakobsen L, et al. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017;376(19):1813-23.","journal-title":"N Engl J Med"},{"issue":"19","key":"key20210719142633_B360","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1700445","article-title":"Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI","volume":"376","author":"Davies","year":"2017","unstructured":"360. Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer S S, et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017;376(19), 1824-34.","journal-title":"N Engl J Med"},{"issue":"5","key":"key20210719142633_B361","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1586\/14779072.2016.1145054","article-title":"The use of optical coherence tomography in acute coronary syndrome","volume":"14","author":"Matsuo","year":"2016","unstructured":"361. Matsuo Y, Kubo T, Akasaka T. The use of optical coherence tomography in acute coronary syndrome. Expert Rev Cardiovasc Ther. 2016;14(5):649-57.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"24","key":"key20210719142633_B362","first-page":"2473","article-title":"Intracoronary Optical Coherence Tomography 2018","volume":"10","author":"Ali","year":"2017","unstructured":"362. Ali ZA, Galougahi, KK, Maehara A, Shlofmitz RA, Ben-Yehuda O, Mintz GS, Stone GW. Intracoronary Optical Coherence Tomography 2018. JACC: Cardiovasc Interv. 2017;10(24), 2473\u201387.","journal-title":"JACC: Cardiovasc Interv"},{"issue":"13","key":"key20210719142633_B363","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.116.024393","article-title":"Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non-ST-Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting)","volume":"134","author":"Meneveau","year":"2016","unstructured":"363. Meneveau N, Souteyrand G, Motreff P, Caussin C, Amabile N, Ohlmann P, et al. Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non-ST-Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting). Circulation. 2016;134(13):906\u201017.","journal-title":"Circulation"},{"issue":"1","key":"key20210719142633_B364","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11936-020-0803-7","article-title":"Physiological assessment of coronary lesions in 2020","volume":"22","author":"Chowdhury","year":"2020","unstructured":"364. Chowdhury M, Osborn EA. Physiological assessment of coronary lesions in 2020. Curr Treat Options Cardiovasc Med. 2020; 22(1):2.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"5","key":"key20210719142633_B365","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.amjmed.2005.02.016","article-title":"How should patients with unstable angina and non-ST-segment elevation myocardial infarction be managed? A meta-analysis of randomized trials","volume":"118","author":"Choudhry","year":"2005","unstructured":"365. Choudhry NK, Singh JM, Barolet A, Tomlinson GA, Detsky AS. How should patients with unstable angina and non-ST-segment elevation myocardial infarction be managed? A meta-analysis of randomized trials. Am J Med. 2005;118(5):465-74.","journal-title":"Am J Med"},{"issue":"2","key":"key20210719142633_B366","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jcin.2011.10.016","article-title":"Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) Trials","volume":"5","author":"Damman","year":"2012","unstructured":"366. Damman P, van Geloven N, Wallentin L, Lagerqvist B, Fox KA, Clayton T, et al. Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) Trials. JACC Cardiovasc Interv. 2012;5(2):191-9.","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"key20210719142633_B367","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.ijcard.2013.05.004","article-title":"The adequacy of myocardial revascularization in patients with multivessel coronary artery disease","volume":"168","author":"Zimarino","year":"2013","unstructured":"367. Zimarino M, Curzen N, Cicchitti V, De Caterina R. The adequacy of myocardial revascularization in patients with multivessel coronary artery disease. Int J Cardiol. 2013;168(3):1748-57.","journal-title":"Int J Cardiol"},{"key":"key20210719142633_B368","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/archinte.163.19.2345","article-title":"Predictors of hospital mortality in the Global Registry of Acute Coronary Events","volume":"163","author":"Granger","year":"2003","unstructured":"368. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med 2003;163:2345\u201353138.","journal-title":"Arch Intern Med"},{"key":"key20210719142633_B369","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCULATIONAHA.116.021886","article-title":"State-of-the-Art Evaluation of Emergency Department Patients Presenting With Potential Acute Coronary Syndromes","volume":"134","author":"Judd","year":"2016","unstructured":"369. Judd E, Hollander JE, Than M, Mueller C. State-of-the-Art Evaluation of Emergency Department Patients Presenting With Potential Acute Coronary Syndromes. Circulation 2016;134:547\u2013564.","journal-title":"Circulation"},{"key":"key20210719142633_B370","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jacc.2009.11.026","article-title":"ICTUS Investigators. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome","volume":"55","author":"Damman","year":"2010","unstructured":"370. Damman P, Hirsch A, Windhausen F, Tijssen JGP, Winter RJ, ICTUS Investigators. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010;55:858\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"69","key":"key20210719142633_B371","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0735-1097(17)33571-4","article-title":"Early invasive strategy and in-hospital survival of diabetics with non-st-elevation Myocardial infarction: a contemporary national insight","author":"Mahmoud","year":"2017","unstructured":"371. Mahmoud AN, Elgendy IY, Mansoor H, Xuerong W, Mojadid MK, Bavry AA, et al. Early invasive strategy and in-hospital survival of diabetics with non-st-elevation Myocardial infarction: a contemporary national insight. JACC. 2017;(69):182.","journal-title":"JACC"},{"issue":"2","key":"key20210719142633_B372","first-page":"219","article-title":"The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease","volume":"1","author":"Sianos","year":"2005","unstructured":"372. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219-27.","journal-title":"EuroIntervention"},{"issue":"9867","key":"key20210719142633_B373","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(13)60141-5","article-title":"Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial","volume":"381","author":"Mohr","year":"2013","unstructured":"373. Mohr FW, Morice MC, Kappetein AP, Feldman TE, St\u00e5hle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629-38.","journal-title":"Lancet"},{"issue":"1","key":"key20210719142633_B374","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0002-9149(83)80003-4","article-title":"Importance of complete revascularization in performance of the coronary bypass operation","volume":"51","author":"Jones","year":"1983","unstructured":"374. Jones EL, Craver JM, Guyton RA, Bone DK, Hatcher CR Jr, Riechwald N. Importance of complete revascularization in performance of the coronary bypass operation. Am J Cardiol. 1983;51(1):7-12.","journal-title":"Am J Cardiol"},{"issue":"28","key":"key20210719142633_B375","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007410","article-title":"Application of the SYNTAX score in interventional cardiology: A systematic review and meta-analysis","volume":"96","author":"Bundhun","year":"2017","unstructured":"375. Bundhun PK, Sookharee Y, Bholee A, Huang F. Application of the SYNTAX score in interventional cardiology: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(28):e7410.","journal-title":"Medicine (Baltimore)"},{"key":"key20210719142633_B376","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.amjcard.2011.04.005","article-title":"Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007","volume":"108","author":"Ranasinghe","year":"2011","unstructured":"376. Ranasinghe I, Alprandi-Costa B, Chow V, Elliott JM, Waites J, Counsell JT, et al. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. Am J Cardiol 2011;108:617\u2013624.","journal-title":"Am J Cardiol"},{"key":"key20210719142633_B377","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jtcvs.2012.05.043","article-title":"Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris","volume":"145","author":"Fukui","year":"2013","unstructured":"377. Fukui T, Tabata M, Morita S, Takanashi S. Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris. J Thorac Cardiovasc Surg 2013;145:1577\u20131583.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"key20210719142633_B378","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/bja\/aew189","article-title":"Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: A prospective observational study","volume":"117","author":"Malm","year":"2016","unstructured":"378. Malm CJ, Hansson EC, Akesson J, Andersson M, Hesse C, Shams Hakimi C, et al. Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: A prospective observational study. Br J Anaesth 2016;117:309\u2013315.","journal-title":"Br J Anaesth"},{"issue":"1","key":"key20210719142633_B379","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.athoracsur.2016.05.116","article-title":"Optimal Timing From Myocardial Infarction to Coronary Artery Bypass Grafting on Hospital Mortality","volume":"103","author":"Nichols","year":"2017","unstructured":"379. Nichols EL, McCullough JN, Ross CS, Kramer RS, Westbrook BM, Klemperer JD, et al. Optimal Timing From Myocardial Infarction to Coronary Artery Bypass Grafting on Hospital Mortality. Ann of Thorac Surg. 2017;103:(1)162\u2013171.","journal-title":"Ann of Thorac Surg"},{"issue":"10023","key":"key20210719142633_B380","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(15)01166-6","article-title":"After Eighty study investigators. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial","volume":"387","author":"Tegn","year":"2016","unstructured":"380. Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, et al. After Eighty study investigators. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet. 2016;387(10023):1057\u20131065.","journal-title":"Lancet"},{"issue":"9489","key":"key20210719142633_B381","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(05)67222-4","article-title":"5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial","volume":"366","author":"Fox","year":"2005","unstructured":"381. Fox KA, Poole-Wilson P, Clayton TC, Henderson RA, Shaw TRD, Wheatley DJ, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet. 2005;366(9489):914\u201320.","journal-title":"Lancet"},{"issue":"5","key":"key20210719142633_B382","article-title":"Routine Invasive Strategies Versus Selective Invasive Strategies for Unstable Angina and non-ST Elevation Myocardial Infarction in the Stent Era","author":"Fanning","year":"2016","unstructured":"382. Fanning JP, Nyong J, Scott IA, Aroney CN, Walters DL. Routine Invasive Strategies Versus Selective Invasive Strategies for Unstable Angina and non-ST Elevation Myocardial Infarction in the Stent Era. Cochrane Database Syst Rev. 2016;(5):CD004815.","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"key20210719142633_B383","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJMoa1701067","article-title":"Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction","volume":"376","author":"Smits","year":"2017","unstructured":"383. Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, et al. Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. N Engl J Med, 2017;376(13):1234\u201344.","journal-title":"N Engl J Med"},{"issue":"7","key":"key20210719142633_B384","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcin.2019.01.227","article-title":"Impact of Intravascular Ultrasound-Guided Percutaneous Coronary Intervention on Long-Term Clinical Outcomes in Patients Undergoing Complex Procedures","volume":"12","author":"Choi","year":"2019","unstructured":"384. Choi KH, Song YB, Lee JM, Lee SY, Park TK, Yang JH, et al. Impact of Intravascular Ultrasound-Guided Percutaneous Coronary Intervention on Long-Term Clinical Outcomes in Patients Undergoing Complex Procedures. JACC Cardiovasc Interv, 2019;12(7):607\u201320.","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"key20210719142633_B385","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10554-019-01555-3","article-title":"Intravascular Ultrasound Guidance Reduces Cardiac Death and Coronary Revascularization in Patients Undergoing Drug-Eluting Stent Implantation: Results From a Meta-Analysis of 9 Randomized Trials and 4724 Patients","volume":"35","author":"Gao","year":"2019","unstructured":"385. Gao XF, Wang ZM, Wang F, Gu Y, Ge Y, et al. Intravascular Ultrasound Guidance Reduces Cardiac Death and Coronary Revascularization in Patients Undergoing Drug-Eluting Stent Implantation: Results From a Meta-Analysis of 9 Randomized Trials and 4724 Patients. Int J Cardiovasc Imaging. 2019;35(2):239\u201347.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"4","key":"key20210719142633_B386","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1590\/S0066-782X2012000400001","article-title":"Use of demonstrably effective therapies in the treatment of acute coronary syndromes:comparison between different Brazilian regions. Analysis of the Brazilian Registry on Acute Coronary Syndromes (BRACE)","volume":"98","author":"Nicolau","year":"2012","unstructured":"386. Nicolau JC, Franken M, Lotufo PA, Carvalho AC, Marin-Neto JA, Gallego F, et al. Use of demonstrably effective therapies in the treatment of acute coronary syndromes:comparison between different Brazilian regions. Analysis of the Brazilian Registry on Acute Coronary Syndromes (BRACE). Arq Bras Cardiol. 2012;98(4):282\u20139.","journal-title":"Arq Bras Cardiol"},{"issue":"4","key":"key20210719142633_B387","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1532-5415.2003.51185.x","article-title":"Falling through the cracks: challenges and opportunities for improving transitional care for persons with continuous complex care needs","volume":"51","author":"Coleman","year":"2003","unstructured":"387. Coleman EA. Falling through the cracks: challenges and opportunities for improving transitional care for persons with continuous complex care needs. J Am Geriatr Soc. 2003;51(4):549\u201355.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"key20210719142633_B388","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1532-5415.2003.51186.x","article-title":"American Geriatrics Society Health Care Systems Committee. Improving the quality of transitional care for persons with complex care needs","volume":"51","author":"Coleman","year":"2003","unstructured":"388. Coleman EA, Boult C, American Geriatrics Society Health Care Systems Committee. Improving the quality of transitional care for persons with complex care needs. J Am Geriatr Soc. 2003;51(4):556\u20137.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"key20210719142633_B389","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00005650-200503000-00007","article-title":"Assessing the quality of preparation for posthospital care from the patient's perspective: the care transitions measure","volume":"43","author":"Coleman","year":"2005","unstructured":"389. Coleman EA, Mahoney E, Parry C. Assessing the quality of preparation for posthospital care from the patient's perspective: the care transitions measure. Med Care. 2005;43(3):246\u201355.","journal-title":"Med Care"},{"issue":"22","key":"key20210719142633_B390","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"Smith","year":"2011","unstructured":"390. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458\u201373.","journal-title":"Circulation"},{"issue":"2","key":"key20210719142633_B391","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ahj.2006.10.037","article-title":"Socioeconomic disparities in outcomes after acute myocardial infarction","volume":"153","author":"Bernheim","year":"2007","unstructured":"391. Bernheim SM, Spertus JA, Reid KJ, Bradley E, Desai RA, Peterson ED, et al. Socioeconomic disparities in outcomes after acute myocardial infarction. Am Heart J. 2007;153(2):313\u20139.","journal-title":"Am Heart J"},{"issue":"10","key":"key20210719142633_B392","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jama.297.10.1063","article-title":"Financial barriers to health care and outcomes after acute myocardial infarction","volume":"297","author":"Rahimi","year":"2007","unstructured":"392. Rahimi AR, Spertus JA, Reid KJ,Bernheim SM, Krumholz HM. Financial barriers to health care and outcomes after acute myocardial infarction. JAMA. 2007;297(10):1063\u201372.","journal-title":"JAMA"},{"issue":"4","key":"key20210719142633_B393","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCOUTCOMES.109.868588","article-title":"The association of cognitive and somatic depressive symptoms with depression recognition and outcomes after myocardial infarction","volume":"2","author":"Smolderen","year":"2009","unstructured":"393. Smolderen KG, Spertus JA, Reid KJ, Buchanan DM, Krumholz HM, Denollet J, et al. The association of cognitive and somatic depressive symptoms with depression recognition and outcomes after myocardial infarction. Circ Cardiovasc Qual Outcomes. 2009;2(4):328\u201337.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"key20210719142633_B394","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjmed.2004.01.009","article-title":"Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials","volume":"116","author":"Taylor","year":"2004","unstructured":"394. Taylor RS, Brown A, Ebrahim S, Jollife J, Noorani H, Becky KR, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116(10):682\u201392.","journal-title":"Am J Med"},{"issue":"3","key":"key20210719142633_B395","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1161\/01.CIR.0000151788.08740.5C","article-title":"Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation","volume":"111","author":"Leon","year":"2005","unstructured":"395. Leon AS, Franklin BA, Costa F, Balady GB, Berra KA, Stewart KJ, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2005;111(3):369\u201376.","journal-title":"Circulation"},{"issue":"1","key":"key20210719142633_B396","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jacc.2009.01.078","article-title":"Cardiac rehabilitation and survival in older coronary patients","volume":"54","author":"Suaya","year":"2009","unstructured":"396. Suaya JA, Stason WB, Ades PA, Normand ST, Shepard DS, et al. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol. 2009;54(1):25\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"key20210719142633_B397","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1161\/CIRCULATIONAHA.104.503995","article-title":"Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review","volume":"112","author":"Iestra","year":"2005","unstructured":"397. Iestra JA, Kromhout D, van der Schouw YT, Grobbee DE, Boshuizen HC, van Staveren WA. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation. 2005;112(6)924\u201334.","journal-title":"Circulation"},{"issue":"1","key":"key20210719142633_B398","first-page":"1","article-title":"Exercise-based cardiac rehabilitation for coronary heart disease","volume":"67","author":"Anderson","year":"2016","unstructured":"398. Anderson L1, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2016 Jan 5;67(1):1-12.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"key20210719142633_B399","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1001\/jama.290.1.86","article-title":"Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review","volume":"290","author":"Critchley","year":"2003","unstructured":"399. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290(1):86\u201397.","journal-title":"JAMA"},{"key":"key20210719142633_B400","volume-title":"The health consequences of smoking\u2014 50 years of progress: a report of the Surgeon General","author":"National Center for Chronic Disease Prevention and Health Promotion(US) Office on Smoking and Health","year":"2014","unstructured":"400. National Center for Chronic Disease Prevention and Health Promotion(US) Office on Smoking and Health. The health consequences of smoking\u2014 50 years of progress: a report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention,(US); 2014."},{"issue":"9","key":"key20210719142633_B401","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jacc.2018.06.036","article-title":"Prevention and Treatment of Tobacco Use. JACC Health Promotion Series","volume":"72","author":"Kalkhoran","year":"2018","unstructured":"401. Kalkhoran S, Benowitz N, Rigotti N. Prevention and Treatment of Tobacco Use.JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(9):1030-45.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"key20210719142633_B402","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/archinte.163.19.2301","article-title":"Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease","volume":"163","author":"Goldenberg","year":"2003","unstructured":"402. Goldenberg I, Jonas M, Tenenbaum A, Boyoko V, Matetzky S, Shotan A, et al. Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med. 2003;163(19):2301\u20135.","journal-title":"Arch Intern Med"},{"issue":"3","key":"key20210719142633_B403","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/ATVBAHA.113.300156","article-title":"Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis","volume":"34","author":"Messner","year":"2014","unstructured":"403. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34(3):509\u201315.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"key20210719142633_B404","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.hrthm.2011.03.038","article-title":"(2011) Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study","volume":"8","author":"Chamberlain","year":"2011","unstructured":"404. Chamberlain AM, Agarwal SK, Folsom AR, et al. (2011) Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm.2011;8(8):1160-6.","journal-title":"Heart Rhythm"},{"issue":"6388","key":"key20210719142633_B405","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/bmj.287.6388.324","article-title":"Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction","volume":"287","author":"Daly","year":"1983","unstructured":"405. Daly LE, Mulcahy R, Graham IM, Hickey N. Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. Br Med J (Clin Res Ed). 1983;287(6388):324-6.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"key20210719142633_B406","article-title":"Smoking status and mortality outcomes following percutaneous coronary intervention","volume":"3","author":"Parasuraman","year":"2020","unstructured":"406. Parasuraman S, Zaman AG, Egred M, Bagnall A, Broadhurst PA, Ahmed J, et al. Smoking status and mortality outcomes following percutaneous coronary intervention. Eur J Prev Cardiol. 2020 Feb 3; 2047487320902325.","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"key20210719142633_B407","doi-asserted-by":"crossref","first-page":"845","DOI":"10.7326\/0003-4819-145-11-200612050-00142","article-title":"Systematic review: smoking cessation intervention strategies for adults and adults in special populations","volume":"145","author":"Ranney","year":"2006","unstructured":"407. Ranney L, Melvin C, Lux L, McClain E, Lohr KN. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006;145(11):845-56.","journal-title":"Ann Intern Med"},{"issue":"23","key":"key20210719142633_B408","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1056\/NEJMsa053935","article-title":"Explaining the decrease in U.S. deaths from coronary disease, 1980\u20132000","volume":"356","author":"Ford","year":"2007","unstructured":"408. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease,1980\u20132000. N Engl J Med. 2007;356(23):2388-98.","journal-title":"N Engl J Med"},{"issue":"9","key":"key20210719142633_B409","article-title":"Smoking reduction interventions for smoking cassation","volume":"9","author":"Lindson","year":"2019","unstructured":"409. Lindson N, Klemperer E, Hong B, Ord\u00f3\u00f1ez-Mena JM, Aveyard P. Smoking reduction interventions for smoking cassation. Cochrane Database Syst Rev. 2019 Sep 30;9(9):CD013183.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"key20210719142633_B410","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jacc.2012.08.1030","article-title":"Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial","volume":"61","author":"Eisenberg","year":"2013","unstructured":"410. Eisenberg MJ, Grandi SM, Gervais A, O\u2019Loughlin J, Paradis G, Rinfret S, et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol 2013; 61(5):524\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"key20210719142633_B411","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/archinternmed.2011.72","article-title":"Bupropion for smoking cessation in patients with acute coronary syndrome","volume":"171","author":"Planer","year":"2011","unstructured":"411. Planer D, Lev I, Elitzur Y, Sharon N, Ouzan E, Pugatsch T, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. Arch Intern Med. 2011;171(12):1055-60.","journal-title":"Arch Intern Med"},{"issue":"5","key":"key20210719142633_B412","article-title":"Nicotine replacement therapy for smoking cessation","volume":"5","author":"Stead","year":"2018","unstructured":"412. Stead LF, Perera R,Bullen C,Mant D, Hartman-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev.2018;5(5):CD000146.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"key20210719142633_B413","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/archinte.160.7.939","article-title":"Effect of smoking cessationon mortality after myocardial infarction: meta-analysis of cohortstudies","volume":"160","author":"Wilson","year":"2000","unstructured":"413. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessationon mortality after myocardial infarction: meta-analysis of cohortstudies. Arch Intern Med. 2000;160(7):939-44.","journal-title":"Arch Intern Med"},{"key":"key20210719142633_B414","author":"Agency for Health Care Research and Quality. (AHRQ)","year":"1996","unstructured":"414. Agency for Health Care Research and Quality. (AHRQ). Clinical Practice Guidelines: Smoking Cessation. No 18. AHCPR Publication No.96-0692; 1996.","journal-title":"Clinical Practice Guidelines: Smoking Cessation"},{"issue":"1","key":"key20210719142633_B415","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Varenicline Phase 3 Study Group. Efficacy of varenicline, analpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placeboor sustained-release bupropion for smoking cessation: a randomized controlled trial","volume":"296","author":"Jorenby","year":"2006","unstructured":"415. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, analpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placeboor sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63. Erratum in JAMA. 2006;296(11):1355.","journal-title":"JAMA"},{"issue":"1","key":"key20210719142633_B416","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.296.1.47","article-title":"Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial","volume":"296","author":"Gonzales","year":"2006","unstructured":"416. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.","journal-title":"JAMA"},{"issue":"5","key":"key20210719142633_B417","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1590\/S1516-31802012000500014","article-title":"Nicotine receptor partial agonists for smoking cessation","volume":"130","author":"Cahill","year":"2012","unstructured":"417. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Sao Paulo Med J.2012;130(5):346-7. (Cochrane Highlights)","journal-title":"Sao Paulo Med J"},{"issue":"10037","key":"key20210719142633_B418","doi-asserted-by":"crossref","first-page":"P2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric isorders EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"Anthenelli","year":"2016","unstructured":"418. Anthenelli RM, Benowitz NL, West R, Russ C, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric isorders EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet.2016; 387(10037):P2507-20.","journal-title":"Lancet"},{"issue":"2","key":"key20210719142633_B419","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/CIRCULATIONAHA.109.869008","article-title":"Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial","volume":"121","author":"Rigotti","year":"2010","unstructured":"419. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010; 121(2):221\u20139.","journal-title":"Circulation"},{"issue":"1","key":"key20210719142633_B420","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.115.019634","article-title":"Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome","volume":"133","author":"Eisenberg","year":"2016","unstructured":"420. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, et al. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation. 2016; 133(1):21\u201330.","journal-title":"Circulation"},{"issue":"12","key":"key20210719142633_B421","doi-asserted-by":"crossref","first-page":"E347","DOI":"10.1503\/cmaj.170377","article-title":"Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital","volume":"190","author":"Windle","year":"2018","unstructured":"421. Windle SB, Dehghani P, Roy N, Old W, Grondin FR, Bhata I, et al. Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital. CMAJ.2018;190(12):E347-E354.","journal-title":"CMAJ"},{"key":"key20210719142633_B422","doi-asserted-by":"crossref","first-page":"152125","DOI":"10.1016\/j.comppsych.2019.152125","article-title":"Combination therapy of varenicline and bupropion in smoking cessation: A meta-analysis of the randomized controlled trials","volume":"95","author":"Zhong","year":"2019","unstructured":"422. Zhong Z, Zhao S, Zhao Y, Xia S. Combination therapy of varenicline and bupropion in smoking cessation: A meta-analysis of the randomized controlled trials. Compr Psychiatry. 2019; 95:152125.","journal-title":"Compr Psychiatry"},{"issue":"23","key":"key20210719142633_B423","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2018.10.020","article-title":"Prevention and Treatment of Tobacco Use","volume":"72","author":"Kalkhoran","year":"2018","unstructured":"423. Kalkhoran S, Benowitz NL, Rigotti N. Prevention and Treatment of Tobacco Use. J Am Coll Cardiol. 2018;72(23):2964-979.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20210719142633_B424","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/add.13534","article-title":"Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game","volume":"112","author":"Benowitz","year":"2017","unstructured":"424. Benowitz NL,Donny EC, Hatsukami DK. Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game. Addiction.2017; 112(1):6\u20137.","journal-title":"Addiction"},{"issue":"2","key":"key20210719142633_B425","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1158\/1055-9965.EPI-14-0739","article-title":"Compensatory smoking from gradual and immediate reduction in cigarette nicotine content","volume":"24","author":"Hatsukami","year":"2015","unstructured":"425. Hatsukami DK, Donny EC, Koopmeiners JS, Benowitz NL. Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. Cancer Epidemiol Biomarkers Prev.2015; 24(2):472\u20136.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20210719142633_B426","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/VHRM.S175970","article-title":"Electronic cigarettes and cardiovascular health: what do we know so far?","volume":"15","author":"MacDonald","year":"2019","unstructured":"426. MacDonald A, Middlekauff HR. Electronic cigarettes and cardiovascular health: what do we know so far? Vasc Health Risk Manag. 2019 jun 21;15:159-74.","journal-title":"Vasc Health Risk Manag"},{"key":"key20210719142633_B427","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","unstructured":"427. Baigent C, Blackwell L, Emberson J, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376: 1670\u201381.","journal-title":"Lancet"},{"issue":"9753","key":"key20210719142633_B428","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","unstructured":"428. Collins R, Reith C, Emberson J,Bhala N, Peto R, Barnes EH, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(9753):2532\u201361.","journal-title":"Lancet"},{"issue":"6","key":"key20210719142633_B429","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transiente ischemic attack","volume":"355","author":"Amarenco","year":"2006","unstructured":"429. Amarenco P, Bogousslavsky J, Callahan A 3rd,Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transiente ischemic attack. N Engl J Med. 2006;355(6):549\u201359.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20210719142633_B430","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1185\/030079902125000787","article-title":"Treatment with atorvastatin to the National Cholesterol Educational Program goal versus \u2018usual\u2019 care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study","volume":"18","author":"Athyros","year":"2002","unstructured":"430. Athyros VG, Papageorgiou AA, Mercouris BR, Athyros VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus \u2019usual\u2019 care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18(4):220\u20138.","journal-title":"Curr Med Res Opin"},{"issue":"22","key":"key20210719142633_B431","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","unstructured":"431. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248\u201361.","journal-title":"N Engl J Med"},{"issue":"9645","key":"key20210719142633_B432","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","unstructured":"432. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372(9645):1231\u20139.","journal-title":"Lancet"},{"issue":"25 Suppl 2","key":"key20210719142633_B433","first-page":"S76","article-title":"2013 AHA \/ ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Eckel","year":"2014","unstructured":"433. Eckel RH, Jakicic JM, Ard JD,de Jesus JM, Houston Miller N, Hubbard VS, et al. et al. 2013 AHA \/ ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S76\u201399.","journal-title":"Circulation"},{"issue":"25 Pt B","key":"key20210719142633_B434","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"Jensen","year":"2014","unstructured":"434. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985\u20133023.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"key20210719142633_B435","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts","volume":"378","author":"Estruch","year":"2018","unstructured":"435. Estruch R, Ros E, Salas-Salvad\u00f3 J, Covas MI, Corella D, Ar\u00f3s F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018 Jun 21;378(25):e34.","journal-title":"N Engl J Med"},{"issue":"8","key":"key20210719142633_B436","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jama.297.8.842","article-title":"Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis","volume":"297","author":"Bjelakovic","year":"2007","unstructured":"436. Bjelakovic G, Nikolova D, Gluud LL,Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007; 297(8):842\u201357.","journal-title":"JAMA"},{"issue":"5","key":"key20210719142633_B437","doi-asserted-by":"crossref","first-page":"943","DOI":"10.36660\/abc.20200407","article-title":"Diretriz Brasileira de Reabilita\u00e7\u00e3o Cardiovascular \u2013 2020","volume":"114","author":"Carvalho","year":"2020","unstructured":"437. Carvalho T, Milani M, Ferraz AS, Silveira AD, Herdy AH, Hossri CAC, et al. Diretriz Brasileira de Reabilita\u00e7\u00e3o Cardiovascular \u2013 2020. Arq Bras Cardiol. 2020; 114(5):943-87.","journal-title":"Arq Bras Cardiol"},{"issue":"9","key":"key20210719142633_B438","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamacardio.2016.3458","article-title":"Association between cardiac rehabilitation participation and health status outcomes after acute myocardial infarction","volume":"1","author":"Kureshi","year":"2016","unstructured":"438. Kureshi F, Kennedy KF, Jones PG, Thomas RJ, Arnold S V., Sharma P, et al. Association between cardiac rehabilitation participation and health status outcomes after acute myocardial infarction. JAMA Cardiol. 2016;1(9):980\u20138.","journal-title":"JAMA Cardiol"},{"issue":"15","key":"key20210719142633_B439","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1161\/CIRCULATIONAHA.107.701466","article-title":"Use of Cardiac Rehabilitation by Medicare Beneficiaries After Myocardial Infarction or Coronary Bypass Surgery","volume":"116","author":"Suaya","year":"2007","unstructured":"439. Suaya JA, Shepard DS, Normand S-LT, Ades PA, Prottas J, Stason WB. Use of Cardiac Rehabilitation by Medicare Beneficiaries After Myocardial Infarction or Coronary Bypass Surgery. Circulation. 2007 Oct 9;116(15):1653 LP \u2013 1662.","journal-title":"Circulation"},{"issue":"3","key":"key20210719142633_B440","first-page":"168","article-title":"Cardiac rehabilitation in patients with acute coronary syndrome with primary percutaneous coronary intervention is associated with improved 10-year survival","volume":"4","author":"Sunamura","year":"2018","unstructured":"440. Sunamura M, Ter Hoeve N, van den Berg-Emons RJG, Boersma E, van Domburg RT, Geleijnse ML. Cardiac rehabilitation in patients with acute coronary syndrome with primary percutaneous coronary intervention is associated with improved 10-year survival. Eur Heart J Qual Care Clin Outcomes. 2018 Jul;4(3):168\u201372.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"2","key":"key20210719142633_B441","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.mayocp.2016.10.014","article-title":"Increasing Cardiac Rehabilitation Participation From 20% to 70%: A Road Map From the Million Hearts Cardiac Rehabilitation Collaborative","volume":"92","author":"Ades","year":"2017","unstructured":"441. Ades PA, Keteyian SJ, Wright JS, Hamm LF, Lui K, Newlin K, et al. Increasing Cardiac Rehabilitation Participation From 20% to 70%: A Road Map From the Million Hearts Cardiac Rehabilitation Collaborative. Mayo Clin Proc. 2017;92(2):234-42.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"key20210719142633_B442","first-page":"98","article-title":"Prognostic value of TIMI score versus GRACE score in ST-segment elevation myocardial infarction","volume":"103","author":"Correia","year":"2014","unstructured":"442. Correia LC, Garcia G, Kalil F, Ferreira F, Carvalhal M, Oliveira R,et al. Prognostic value of TIMI score versus GRACE score in ST-segment elevation myocardial infarction. Arq Bras Cardiol. 2014 Aug;103(2):98-106.","journal-title":"Arq Bras Cardiol"},{"issue":"8","key":"key20210719142633_B443","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/CIR.0b013e31829b5b44","article-title":"Exercise standards for testing and training: A scientific statement from the American heart association","volume":"128","author":"Fletcher","year":"2013","unstructured":"443. Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, et al. Exercise standards for testing and training: A scientific statement from the American heart association. Circulation. 2013;128(8):873\u2013934.","journal-title":"Circulation"},{"issue":"4","key":"key20210719142633_B444","first-page":"267","article-title":"Arquivos Brasileiros de Cardiologia I CONSENSO NACIONAL DE REABILITA\u00c7\u00c3O CARDIOVASCULAR","volume":"69","author":"Costa","year":"1997","unstructured":"444. Costa RVC, Braga AMW, Carlos A. Arquivos Brasileiros de Cardiologia I CONSENSO NACIONAL DE REABILITA\u00c7\u00c3O CARDIOVASCULAR. Arq Bras Cardiol. 1997;69(4):267\u201391.","journal-title":"Arq Bras Cardiol"},{"issue":"6","key":"key20210719142633_B445","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.amjcard.2012.11.058","article-title":"Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"111","author":"Loh","year":"2013","unstructured":"445. Loh JP, Pendyala LK, Kitabata H, Torguson R, Chen F, Kent KM, et al. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol.2013;111(6):841-5.","journal-title":"Am J Cardiol"},{"key":"key20210719142633_B446","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2016.10.006","article-title":"Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after","volume":"183","author":"Zettler","year":"2017","unstructured":"446. Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, et al. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after. Am Heart J. 2017J Jan; 183:62-8.","journal-title":"Am Heart J"},{"issue":"15","key":"key20210719142633_B447","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jacc.2013.11.032","article-title":"Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the swap-2 study (switching anti platelet-2)","volume":"63","author":"Angiolillo","year":"2014","unstructured":"447. Angiolillo DJ, Curzen N, Gurbel P, Vaitkus P, Lipkin F, Li W, et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the swap-2 study (switching anti platelet-2). J Am Coll Cardiol. 2014;63(15):1500\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20210719142633_B448","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1160\/TH16-04-0340","article-title":"A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome","volume":"117","author":"Pourdjabbar","year":"2017","unstructured":"448. Pourdjabbar A, Hibbert B, Chong AY, Le May MR, Labinaz M, Simard T, et al. A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. Thromb Haemost. 2017;117(2):303\u201310.","journal-title":"Thromb Haemost"},{"issue":"23","key":"key20210719142633_B449","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1161\/CIRCULATIONAHA.118.033983","article-title":"Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease results of the SWAP-4 study","volume":"137","author":"Franchi","year":"2018","unstructured":"449. Franchi F, Rollini F, Rios JR, Rivas A, Agarwal M, Kureti M, et al. Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease results of the SWAP-4 study. Circulation. 2018;137(23):2450\u201362.","journal-title":"Circulation"},{"issue":"20","key":"key20210719142633_B450","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","unstructured":"450. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation. 2017;136(20):1955\u201375.","journal-title":"Circulation"},{"issue":"1","key":"key20210719142633_B451","first-page":"213","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"Valgimigli","year":"2017","unstructured":"451. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2017;53(1):213\u201354.","journal-title":"Eur Heart J"},{"issue":"14","key":"key20210719142633_B452","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","unstructured":"452. Roe MT, Armstrong PW, Fox KAA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297\u2013309.","journal-title":"N Engl J Med"},{"issue":"19","key":"key20210719142633_B453","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-Term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","unstructured":"453. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-Term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791\u2013800.","journal-title":"N Engl J Med"},{"issue":"17","key":"key20210719142633_B454","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/eurheartj\/ehz821","article-title":"Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54","volume":"41","author":"Furtado","year":"2020","unstructured":"454. Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, et al. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. Eur Heart J.2020;41(17):1625-32.","journal-title":"Eur Heart J"},{"issue":"23","key":"key20210719142633_B455","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","unstructured":"455. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371(23):2155\u201366.","journal-title":"N Engl J Med"},{"issue":"13","key":"key20210719142633_B456","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","unstructured":"456. Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2015 Apr 7;65(13):1298-310.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"key20210719142633_B457","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamacardio.2016.2110","article-title":"Antiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction","volume":"1","author":"Bonaca","year":"2016","unstructured":"457. Bonaca MP, Sabatine MS. Antiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction. JAMA Cardiol. 2016 Sep 1;1(6):627-8.","journal-title":"JAMA Cardiol"},{"issue":"10073","key":"key20210719142633_B458","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","unstructured":"458. Costa F, van Klaveren D, James S, Heg D, R\u00e4ber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet.2017;389(10073):1025-34.","journal-title":"Lancet"},{"issue":"16","key":"key20210719142633_B459","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of Dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","unstructured":"459. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SLT, Gershlick AH, Cohen DJ, et al. Development and validation of a prediction rule for benefit and harm of Dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA - J Am Med Assoc 2016;315(16):1735\u201349.","journal-title":"JAMA - J Am Med Assoc"},{"issue":"14","key":"key20210719142633_B460","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","unstructured":"460. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-30.","journal-title":"N Engl J Med"},{"issue":"10117","key":"key20210719142633_B461","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","unstructured":"461. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):205-18.","journal-title":"Lancet"},{"issue":"10151","key":"key20210719142633_B462","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la","volume":"392","author":"Vranckx","year":"2018","unstructured":"462. Vranckx P, Valgimigli M, J\u00fcni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la. Lancet. 2018;392(10151):940\u20139.","journal-title":"Lancet"},{"issue":"16","key":"key20210719142633_B463","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.jacc.2019.08.997","article-title":"Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI","volume":"74","author":"Takahashi","year":"2019","unstructured":"463. Takahashi K, Serruys PW, Chichareon P, Chang CC, Tomaniak M, Modolo R, et al. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. J Am Coll Cardiol. 2019 Oct 22;74(16):2015-27.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"key20210719142633_B464","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without Aspirin in High-Risk Patients after PCI","volume":"381","author":"Mehran","year":"2019","unstructured":"464. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019;381(21):2032-42.","journal-title":"N Engl J Med"},{"issue":"6","key":"key20210719142633_B465","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","article-title":"The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis","volume":"142","author":"O\u2019Donoghue","year":"2020","unstructured":"465. O\u2019Donoghue ML, Murphy SA, Sabatine MS. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Circulation. 2020 Aug 11;142(6):538-45.","journal-title":"Circulation"},{"issue":"10","key":"key20210719142633_B466","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non- ST-elevation acute coronary syndrome: The clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial","volume":"110","author":"Fox","year":"2004","unstructured":"466. Fox KAA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non- ST-elevation acute coronary syndrome: The clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation 2004;110(10):1202\u20138.","journal-title":"Circulation"},{"issue":"7","key":"key20210719142633_B467","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/hrt.2007.134486","article-title":"Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation","volume":"94","author":"Lopes","year":"2008","unstructured":"467. Lopes RD,Pieper KS, Horton JR, Al-Khatib SM, Newby LK,Mehta RH, et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart. 2008,94(7):867-73.","journal-title":"Heart"},{"issue":"9872","key":"key20210719142633_B468","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","unstructured":"468. Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013;381(9872):1107\u201315.","journal-title":"Lancet"},{"issue":"10","key":"key20210719142633_B469","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40265-020-01323-x","article-title":"RE-DUAL PCI Steering Committee and Investigators. Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With\/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial","volume":"80","author":"Nicolau","year":"2020","unstructured":"469. Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, et al. RE-DUAL PCI Steering Committee and Investigators. Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With\/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. Drugs. 2020 Jul;80(10):995\u20131005.","journal-title":"Drugs"},{"issue":"19","key":"key20210719142633_B470","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/eurheartj\/ehy162","article-title":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials","volume":"39","author":"Golwala","year":"2018","unstructured":"470. Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, Oldgren J, Ten Berg JM, Kimura T, Hohnloser SH, Lip GYH, Bhatt DL. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2018; 39(19):1726-1735.","journal-title":"Eur Heart J"},{"issue":"46","key":"key20210719142633_B471","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1093\/eurheartj\/ehz823","article-title":"Antithrombotic therapy after acute coronary syndrome and\/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot","volume":"40","author":"Lopes","year":"2019","unstructured":"471. Lopes RD, Hong H, Alexander JH. Antithrombotic therapy after acute coronary syndrome and\/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot. Eur Heart J. 2019 Dec 7;40(46):3768\u201370.","journal-title":"Eur Heart J"},{"issue":"46","key":"key20210719142633_B472","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"40","author":"Gargiulo","year":"2019","unstructured":"472. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019 Dec 7;40(46):3757-67.","journal-title":"Eur Heart J"},{"issue":"3Supl.3","key":"key20210719142633_B473","first-page":"1","article-title":"Sociedade Brasileira de Cardiologia.. 7\u00aa Diretriz Brasileira de Hipertens\u00e3o Arterial","volume":"107","author":"Malachias","year":"2016","unstructured":"473. Malachias MVB, Souza WKSB, Plavnik FL, Rodrigues CIS, Brand\u00e3o AA, Neves MFT, et al,Sociedade Brasileira de Cardiologia.. 7\u00aa Diretriz Brasileira de Hipertens\u00e3o Arterial. Arq Bras Cardiol 2016; 107(3Supl.3):1-83.","journal-title":"Arq Bras Cardiol"},{"issue":"7","key":"key20210719142633_B474","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/HJH.0b013e32832d7370","article-title":"ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study","volume":"27","author":"Sleight","year":"2009","unstructured":"474. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27(7):1360\u20139.","journal-title":"J Hypertens"},{"issue":"12","key":"key20210719142633_B475","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1517\/14656566.2011.579106","article-title":"What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist?","volume":"12","author":"Banach","year":"2011","unstructured":"475. Banach M, Michalska M, Kjeldsen SE, Ma\u0142yszko J, Mikhailidis DP, Rysz J. What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother. 2011;12(12):1835\u201344.","journal-title":"Expert Opin Pharmacother"},{"issue":"23","key":"key20210719142633_B476","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehq328","article-title":"J-curve revisited: an analysis of the Treating to New Targets (TNT) Trial","volume":"31","author":"Bangalore","year":"2010","unstructured":"476. Bangalore S, Messerli FH, Wun C, Zuckerman AL, DeMicco D, Kostis JB,et al. J-curve revisited: an analysis of the Treating to New Targets (TNT) Trial. Eur Heart J. 2010; 31(23):2897\u2013908.","journal-title":"Eur Heart J"},{"issue":"22","key":"key20210719142633_B477","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A Randomized Trial of Intensive versus Standard Blood-Pressure Control","volume":"373","author":"SPRINT Research Group","year":"2015","unstructured":"477. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. Erratum in: N Engl J Med. 2017 Dec 21;377(25):2506.","journal-title":"N Engl J Med"},{"issue":"12","key":"key20210719142633_B478","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results","volume":"247","year":"1982","unstructured":"478. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247(12):1707\u201314.","journal-title":"JAMA"},{"issue":"8251","key":"key20210719142633_B479","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0140-6736(81)91101-6","article-title":"Effect On Mortality of Metoprolol In Acute Myocardial Infarction. A Double-blind Randomised Trial","volume":"318","author":"Hjalmarson","year":"1981","unstructured":"479. Hjalmarson \u00c5, Herlitz J, M\u00e1lek I, Ryd\u00e9n L, Vedin A, Waldenstr\u00f6m A, et al. Effect On Mortality of Metoprolol In Acute Myocardial Infarction. A Double-blind Randomised Trial. Lancet. 1981;318(8251):823\u20137.","journal-title":"Lancet"},{"issue":"13","key":"key20210719142633_B480","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jacc.2015.07.047","article-title":"Effect of Beta-Blocker Dose on Survival after Acute Myocardial Infarction","volume":"66","author":"Goldberger","year":"2015","unstructured":"480. Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al. Effect of Beta-Blocker Dose on Survival after Acute Myocardial Infarction. J Am Coll Cardiol. 2015;66(13):1431\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"key20210719142633_B481","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"B-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease","volume":"308","author":"Bangalore","year":"2012","unstructured":"481. Bangalore S, Steg G, Deedwania P, Crowley K. B-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease. J Am Med Assoc. JAMA. 2012;308(13):1340\u20139.","journal-title":"J Am Med Assoc. JAMA"},{"issue":"1","key":"key20210719142633_B482","first-page":"6","article-title":"Clinical outcomes at 30 days in the Brazilian Registry of Acute Coronary Syndromes (ACCEPT)","volume":"100","author":"Piva e Mattos","year":"2013","unstructured":"482. Piva e Mattos LA, Berwanger O, Santos ES, Reis HJ, Romano ER, Petriz JL,et al. Clinical outcomes at 30 days in the Brazilian Registry of Acute Coronary Syndromes (ACCEPT). Arq Bras Cardiol. 2013 Jan;100(1):6-13.","journal-title":"Arq Bras Cardiol"},{"issue":"6","key":"key20210719142633_B483","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJM200002103420603","article-title":"Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy","volume":"342","author":"Lachin","year":"2000","unstructured":"483. Lachin JM, Genuth S, Cleary P. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy. N Engl J Med. 2000;342(6):381\u20139.","journal-title":"N Engl J Med"},{"issue":"15","key":"key20210719142633_B484","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"Follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","unstructured":"484. Holman RR, Paul SK, Bethel MA. Follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20210719142633_B485","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2337\/dc17-1144","article-title":"The legacy effect in type 2 diabetes:impactofearlyglycemic control on future complications (the Diabetes & Aging study)","volume":"42","author":"Laiteerapong","year":"2019","unstructured":"485. Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes:impactofearlyglycemic control on future complications (the Diabetes & Aging study). Diabetes Care. 2019;42(3):416\u201326.","journal-title":"Diabetes Care"},{"issue":"24","key":"key20210719142633_B486","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of Intensive Glucose Lowering in Type 2 Diabetes","volume":"358","author":"Gerstein","year":"2008","unstructured":"486. Gerstein C, Miller M, Byington R. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008;358(24):2545\u201359.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"key20210719142633_B487","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc20-S002","article-title":"Standards of Medical Care in Diabetes \u2014 2020","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"487. American Diabetes Association. Standards of Medical Care in Diabetes \u2014 2020. Diabetes Care. 2020 Jan;43((Suppl 1):S14-S31).","journal-title":"Diabetes Care"},{"key":"key20210719142633_B488","article-title":"FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function","author":"U.S. Food and Drug Administration","unstructured":"488. U.S. Food and Drug Administration. FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function.[Internet]. [Cited in 2019 Apr 12] Available from: Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM494140.pdf","journal-title":"Internet"},{"issue":"4","key":"key20210719142633_B489","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2015-3754","article-title":"Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study","volume":"101","author":"Aroda","year":"2016","unstructured":"489. Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab. 2016;101(4):1754\u201361.","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"key20210719142633_B490","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: Systematic review and meta-analysis of cardio","volume":"139","author":"Zelniker","year":"2019","unstructured":"490. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: Systematic review and meta-analysis of cardio. Circulation. 2019;139(17):2022\u201331.","journal-title":"Circulation"},{"issue":"22","key":"key20210719142633_B491","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction","volume":"139","author":"Furtado","year":"2019","unstructured":"491. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation. 2019;139222516-27.,Circulation 2019; 139(22): 2516-27.","journal-title":"Circulation"},{"key":"key20210719142633_B492","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","unstructured":"492. McMurray JJ V, Solomon SD, Inzucchi SE, K\u01ffber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019,381:1995-2008.","journal-title":"N Engl J Med"},{"issue":"24","key":"key20210719142633_B493","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","unstructured":"493. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"14","key":"key20210719142633_B494","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","unstructured":"494. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"18","key":"key20210719142633_B495","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","unstructured":"495. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"key20210719142633_B496","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","unstructured":"496. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-107.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20210719142633_B497","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","unstructured":"497. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22.","journal-title":"N Engl J Med"},{"key":"key20210719142633_B498","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plefa.2018.01.001","article-title":"Safety and tolerability of prescription omega-3 fatty acids: A systematic review and meta-analysis of randomized controlled trials","volume":"129","author":"Chang","year":"2018","unstructured":"498. Chang CH, Tseng PT, Chen NY, Lin PC, Lin PY, Chang JPC, et al. Safety and tolerability of prescription omega-3 fatty acids: A systematic review and meta-analysis of randomized controlled trials. Prostaglandins Leukot Essent Fat Acids. 2018 Feb;129:1-12.","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"issue":"18","key":"key20210719142633_B499","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1093\/eurheartj\/ehp256","article-title":"Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial","volume":"30","author":"Moukarbel","year":"2009","unstructured":"499. Moukarbel G V, Signorovitch JE, Pfeffer MA, McMurray JJ V, White HD, Maggioni AP, et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J. 2009;30(18):2226\u201332.","journal-title":"Eur Heart J"},{"issue":"1","key":"key20210719142633_B500","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1053\/j.gastro.2011.03.049","article-title":"Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy","volume":"141","author":"Lin","year":"2011","unstructured":"500. Lin KJ, Hernandez-Diaz S, Garcia Rodriguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 2011;141(1):71\u20139.","journal-title":"Gastroenterology"},{"issue":"14","key":"key20210719142633_B501","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1056\/NEJMoa025028","article-title":"Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly","volume":"348","author":"Nichol","year":"2003","unstructured":"501. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348(14):1322\u201332.","journal-title":"N Engl J Med"},{"key":"key20210719142633_B502","author":"Brasil. Ministerio da Sa\u00fade","unstructured":"502. Brasil. Ministerio da Sa\u00fade. Manual de Normas e Procedimentos para Vacina\u00e7\u00e3o [Internet]. [Citado em 2020 Jan 12]. Dispon\u00edvel em: http:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/manual_procedimentos_vacinacao.pdf","journal-title":"Manual de Normas e Procedimentos para Vacina\u00e7\u00e3o [Internet]"},{"issue":"12","key":"key20210719142633_B503","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","unstructured":"503. Ridker PM, Everett B, Thuren T, Mac Fadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377(12): 1119\u201331.","journal-title":"N Engl J Med"},{"issue":"26","key":"key20210719142633_B504","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","unstructured":"504. Tardif JC, Kouz S, Waters DD, Bertrand D, Diaz R, Maggioni A, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Eng J Med. 2019;381(26):2497-505.","journal-title":"N Eng J Med"},{"issue":"3 supl 1","key":"key20210719142633_B505","first-page":"1","article-title":"Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Inst\u00e1vel e Infarto Agudo do Mioc\u00e1rdio sem Supradesn\u00edvel do Segmento ST (II Edi\u00e7\u00e3o, 2007) - Atualiza\u00e7\u00e3o 2013\/2014","volume":"102","author":"Nicolau","year":"2014","unstructured":"505. Nicolau, JC,Timerman A, Marin-Neto J\u00c1, Piegas LS, Barbosa CJ, Franci A, et al, Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Inst\u00e1vel e Infarto Agudo do Mioc\u00e1rdio sem Supradesn\u00edvel do Segmento ST (II Edi\u00e7\u00e3o, 2007) - Atualiza\u00e7\u00e3o 2013\/2014. Arq Bras Cardiol. 2014;102(3 supl 1):1-61.","journal-title":"Arq Bras Cardiol"},{"issue":"7536","key":"key20210719142633_B506","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bmj.38695.605440.AE","article-title":"Euro Heart Survey Investigators. Predicting prognosis in stable angina\u2013results from the Euro heart survey of stable angina: prospective observational study","volume":"332","author":"Daly","year":"2006","unstructured":"506. Daly CA, De Stavola B, Sendon JL, Tavazzi L, Boersma E, Clemens F, et al. Euro Heart Survey Investigators. Predicting prognosis in stable angina\u2013results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;332(7536):262-7.","journal-title":"BMJ"},{"issue":"4","key":"key20210719142633_B507","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","unstructured":"507. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T,et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277-314.","journal-title":"J Am Soc Echocardiogr"},{"issue":"11","key":"key20210719142633_B508","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/ehjci\/jew333","article-title":"2014_2016 EACVI Scientific Documents Committee. EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review","volume":"18","author":"Steeds","year":"2017","unstructured":"508. Steeds RP, Garbi M, Cardim N, Kasprzak JD, Sade E, Nihoyannopoulos P, et al. 2014_2016 EACVI Scientific Documents Committee. EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. Eur Heart J Cardiovasc Imaging. 2017;18(11):1191-204.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"key20210719142633_B509","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","unstructured":"509. Knuuti J,Wijins W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al, 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart j. 2020;41(3):407-77.","journal-title":"Eur Heart j"},{"issue":"4","key":"key20210719142633_B510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062080","article-title":"Circulating biomarkers for redicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses","volume":"8","author":"van Holten","year":"2013","unstructured":"510. van Holten TC, Waanders LF, de Groot PG, Vissers J, Hoefer IE, Pasterkamp G,et al. Circulating biomarkers for redicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One. 2013;8(4):e62080.","journal-title":"PLoS One"},{"issue":"7","key":"key20210719142633_B511","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jacc.2017.06.030","article-title":"Biomarker-based risk model to predict cardiovascular mortality in patients with stable coronary disease","volume":"70","author":"Lindholm","year":"2017","unstructured":"511. Lindholm D, Lindback J, Armstrong PW, Budaj A, Cannon CP, Granger CB, et al. Biomarker-based risk model to predict cardiovascular mortality in patients with stable coronary disease. J Am Coll Cardiol. 2017;70(7):813-26.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"key20210719142633_B512","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jacc.2013.03.072","article-title":"Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes","volume":"62","author":"Eapen","year":"2013","unstructured":"512. Eapen DJ, Manocha P, Patel RS, Hammadah M, Veledar E, Wassel C, et al. Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. J Am Coll Cardiol. 2013;62(4):329-37.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20210719142633_B513","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ahj.2013.07.035","article-title":"Prognostic value of stress imaging after revascularization: a systematic review of stress echocardiography and stress nuclear imaging","volume":"167","author":"Harb","year":"2014","unstructured":"513. Harb SC, Marwick TH. Prognostic value of stress imaging after revascularization: a systematic review of stress echocardiography and stress nuclear imaging Am Heart J. 2014;167(1):7-85.","journal-title":"Am Heart J"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/abccardiol.org\/article\/diretrizes-da-sociedade-brasileira-de-cardiologia-sobre-angina-instavel-e-infarto-agudo-do-miocardio-sem-supradesnivel-do-segmento-st-2021\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:05:27Z","timestamp":1747386327000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/diretrizes-da-sociedade-brasileira-de-cardiologia-sobre-angina-instavel-e-infarto-agudo-do-miocardio-sem-supradesnivel-do-segmento-st-2021\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":513,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7,15]]}},"alternative-id":["10.36660\/abc.20210180"],"URL":"https:\/\/doi.org\/10.36660\/abc.20210180","relation":{},"ISSN":["0066-782X","1678-4170"],"issn-type":[{"value":"0066-782X","type":"print"},{"value":"1678-4170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}